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  Abstract 
Small molecule hydrogen bond donors have emerged as versatile catalysts in asymmetric 
synthesis.  Within this class, chiral BINOL phosphoric acid is regarded as one of the pioneer 
catalysts used in several asymmetric transformations.  The ability of the catalyst to activate the 
substrates could be controlled in two different ways. (1) Dual activation/bifunctional activation of 
substrate by hydrogen bond interactions or ion pairing with phosphoric acid or (2) By forming 
chiral BINOL phosphate metal complex that could significantly alter the interactions in chiral 
space.  In particular, chiral alkaline earth metal phosphate complexes have unique advantages as 
catalysts owing to the ubiquitous availability of alkaline earth metals, strong Brønsted basicity of 
their counterions, mild but significant Lewis acidity of the metal and their ability to coordinate at 
multiple reactive sites due to large ionic radius.   
Chapter 1 summarizes the recent development of alkaline earth metal complexes in asymmetric 
catalysis.  My thesis dissertation is focused on the application of chiral alkaline earth metal 
phosphate complexes in novel asymmetric reactions.  
In Chapter 2, we disclosed an efficient asymmetric one-pot synthesis of chiral 1,3-oxazolidines 
and chiral 1,3-oxazinanes.  Chiral oxazolidines and oxazinanes are widely used as auxiliaries in 
asymmetric transition metal catalysis and also key structural motifs in natural products with 
biological activities.  We developed a new synthetic method for chiral 1,3-oxazolidines which 
follows the enantioselective addition of alcohols to imines catalyzed by chiral 3,3’-
(triisopropylphenyl)-derived BINOL magnesium phosphate to form hemiaminal intermediate, 
x 
 
which then undergoes mild base mediated intramolecular nucleophilic substitution to afford highly 
enantioselective 1,3-oxazolidines and 1,3-oxazinanes in good yields. 
In Chapter 3, we developed the first catalytic enantioselective desymmetrization process for 
the synthesis of novel axially chiral cyclohexylidene oxime ethers.  Even though these molecules 
were found to be optically active in 1910, methods to synthesize these molecules are scarce.  We 
have developed an efficient desymmetrization process of 4-phenyl cyclohexanones with 
phenoxyamines catalyzed by chiral BINOL strontium phosphate complex to afford highly 
enantioselective products.  We then extended this methodology to the dynamic kinetic resolution 
of 2-substituted cyclohexanones to form chiral 2-substituted cyclohexyl oximes in good 
enantioselectivities, as demonstrated in Chapter 4.  We further demonstrated the utility of these 
compounds by converting them to chiral 2-aryl cyclohexylamines which are important synthetic 
intermediates. 
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1 Asymmetric reactions catalyzed by chiral alkaline earth metal complexes 
1.1  Chirality and asymmetric synthesis: 
Chirality is a property, which is derived from the Greek word “chiral” which in general means 
“handedness”.  Any molecule that is non-superimposable to its mirror image is known to be a 
“chiral molecule” and the mirror images are called as “enantiomers”.  Chiral molecules play a 
prominent role in biological systems, because all amino acids, proteins, carbohydrates, enzymes, 
etc. are chiral compounds.1  Although, enantiomers have same chemical structure, they will 
interact with the biological systems in different way in three-dimensional structures and exhibit 
different properties such as pharmacokinetics, metabolism, toxicology, etc.  Piutti in 1886, first 
observed the notable taste difference in asparagines, in which the S-isomer is tasteless whereas the 
R-isomer is sweet.  The importance of chiral molecules in pharmaceutical compounds was realized 
in 1960’s when thalidomide racemate was prescribed for morning sickness.  The research showed 
that R enantiomer of thalidomide has desired analgesic property, but S isomer caused teratogenesis, 
that led to defects in babies2. 
Due to the prominence of chiral compounds in wide range of areas such as medicinal, 
biological and materials, the asymmetric synthesis of these compounds has been one of the major 
research interests in modern synthetic organic chemistry.  The general asymmetric methods 
include chiral resolution of mixture of enantiomers, stereospecific synthesis (stoichiometric 
amount of chiral starting material is used) and asymmetric catalysis (chiral catalyst in used).  
Asymmetric catalysis has significant advantages over other methods because small amount of 
chiral catalyst (as low as 1%) could produce excellent enantioselective products and also atom 
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economical.  In 2001, the Noble Prize in Chemistry was awarded to three scientists, Dr. William 
S. Knowles, Dr. K. Barry Sharpless and Dr. Ryoji Noyori for their contribution in the development 
of asymmetric synthesis3 and since then the field of asymmetric catalysis is ever-expanding to new 
horizons. 
 
Figure 1.1 Asparagine (1), Thalidomide (2). 
1.2 Chiral alkaline earth metal complexes: 
Many new and versatile methodologies have been discovered in the asymmetric synthesis of 
optically active compounds.  Most of these reactions are driven by chiral metal catalysts and have 
achieved excellent enantioselective products in numerous asymmetric reactions.4  In modern 
synthetic organic chemistry, the development of environmentally benign synthetic methods has 
attracted major attention in the viewpoint of green chemistry.  That means employing less harmful 
and less toxic catalysts, reagents, solvents and also to develop efficient chemical processes that 
generate less byproducts and curtail damage to the environment.  In this regard, chiral complexes 
of alkaline earth metals Magnesium (Mg), Calcium (Ca), Strontium (Sr) and Barium (Ba) as 
efficient catalysts in asymmetric synthesis has gained recent attention.   
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Alkaline earth metals are ubiquitous in earth’s crust and show the follwoing characteristic 
features: (a) due to the low electronegativity, their counterions show strong Brønsted basicity (b) 
stable divalent oxidation state (c) they have large ionic radius, which will allow for multiple 
coordination sites and (d) they exhibit mild but significant Lewis acidity.  Because of these 
chemical characteristics, by meticulous design of chiral environment around the alkaline earth 
metal they could serve as efficient stereoselective catalysts in asymmetric catalysis.5  
1.3 Activation mode of alkaline earth metal complexes:  
  
Figure 1.2 Activation mode  
Three types of activation mode have been reported for the coordination of chiral alkaline earth 
metal complexes with substrates.  In type I, the metal (M) forms complex with ligand through two 
covalent bonds.  The advantage for this type is chiral environment is strictly controlled because of 
tight connection of ligand with metal.  These complexes are formed with chiral anionic ligands.  
In type II activation mode, the complex is formed with one covalent bond and one coordinate bond 
between metal and ligand in more than bidentate fashion.  For these complexes, asymmetric 
environment is controlled based on the coordination of the free counter anion (Y) and also by using 
playing with different counter anions reactivity of the complex can be changed.  The type III mode 
is deemed to be challenging to control the chiral environment, because metal and ligand are not 
bonded with covalent bonds.  However, recent reports showed that alkaline earth metals have 
significant Lewis acidity to form complex with coordinative ligands and in addition, these 
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complexes are more stable to air and moisture compared to type I and type II complexes.  Based 
on the different activation modes, several chiral ligands have been developed to form complexes 
with alkaline earth metals and applied as chiral catalysts in many important synthetic 
transformations.  The following sections of this chapter have been divided based on the alkaline 
earth metal complexes formed with different chiral ligands and their applications in asymmetric 
synthesis. 
1.4 Complexes with chiral bissulfonamide type ligands: 
Evans first developed the magnesium bissulfonamide complex prepared by treating chiral (S, 
S)-bissulfonamide derived from 1,2-diphenylethylenediamine with dimethylmagnesium to 
catalyze the enantioselective amination of N-Acyloxazolidinones, 4 with di-tert-butyl 
azodicarboxylate as the electrophilic nitrogen source.6  Kobayashi7 et al. reported asymmetric 1,4-
addition reactions of malonates, 6 with chalcones, 7 employing strontium metal complex yielding 
products with excellent enantioselectivities.  The complex is formed by reacting chiral 
bissulfonamide ligand with strontium isopropoxide (Sr(OiPr)2).  In addition, they also showed 
upon using Sr(HMDS)2 afforded more active catalyst.  Furthermore, they reported asymmetric 
Mannich reactions of sulfonylimidates, 9 with imines, 10 using this methodology.  Reactions with 
chiral bissulfonamide ligand follow type I activation mode in which metal and ligand are 
connected with two covalent bonds in bidentate fashion (Figure 1.3). 
1.5 Complexes with chiral BINOL type ligands: 
Chiral BINOL derivatives one of the versatile ligands used as catalysts in many asymmetric 
reactions.  In these compounds, the ligand coordinates to the metal in bidentate fashion leading to 
the strict control of asymmetric environment.  The BINOL derived alkaline earth metal complexes 
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show strong Brønsted basicities and also the coordination of metal to substrates can be controlled 
due to the significant Lewis acidity of the alkaline earth metals. 
Figure 1.3 Asymmetric reactions catalyzed by chiral bissulfonamide alkaline earth metal 
complexes. 
 
Figure 1.4 Chiral BINOL derived alkaline earth metal complexes. 
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1.5.1 Reactions catalyzed by BINOL derived calcium complexes:  
Yamada, reported asymmetric Morita-Baylis-Hillman reaction of cylopentenone, 15 with 3-
phenylpropanal, 16 in presence of calcium complex of BINOL, 12a and tributylphosphine.8  The 
catalyst serves as Lewis acid catalyst to afford products with good yield and moderate 
enantioselectivity. (Figure 1.5). 
 
Figure 1.5 Calcium-BINOL complex catalyzed Morita-Baylis-Hillman reaction. 
 
Figure 1.6 Asymmetric reactions catalyzed by calcium-BINOL complexes. 
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Kumaraswamy et al. reported asymmetric Michael reaction of malonates and β-ketoesters to 
α,β-unsaturated carbonyl compounds catalyzed by calcium BINOL complex.  They also applied 
this methodology for asymmetric epoxidation of chalcones with tert-butyl hydroperoxide 
(tBuOOH).9 (Figure 1.6) 
1.5.2 Reactions catalyzed by BINOL derived barium complexes: 
 
Figure 1.7 Asymmetric Aldol reaction catalyzed by barium-BINOL complex. 
Shibasaki prepared barium complex of BINOL, 14 by treating two equivalents of BINOL 
monomethyl ether with barium alkoxide in which barium coordinates to two BINOL molecules in 
bidentate fashion.  This complex was used in the asymmetric aldol reaction of ketones, 26 with 
aldehydes, 25 to give products with excellent yields and good enantioselectivities. They also 
reported asymmetric aldol-type reaction of β,γ-unsaturated esters, 29 to aldehydes, 28 to form 
Morita-Baylis-Hillman type products, 30 after isomerization in high yields and excellent 
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enantioselectivities.10  Kobayashi reported 3,3’-disilyl-substituted BINOL derivative could also be 
used in aldol reaction to give products, 33 with moderate selectivity.11 (Figure 1.7)  
Kobayashi et al. also reported asymmetric Friedel-Crafts type alkylation reaction of indoles 
with chalcone derivatives in presence of H8-BINOL derived barium complex to afford excellent 
enantioselective products.12  In this the complex prepared by treating H8-BINOL derived ligand 
with Ba(HMDS)2 proved to be more active compared to the complex prepared from barium 
alkoxide.  It was proposed in the mechanism that the acidic proton of indole was deprotonated by 
the chiral barium complex in the first step to form Barium-indole species. (Figure 1.8) 
 
Figure 1.8 Friedel-Crafts type alkylation catalyzed by barium-BINOL complex. 
1.6 Complexes with chiral diol ligands: 
Figure 1.9 Chiral calcium alkoxide catalyzed asymmetric aldol reaction. 
Noyori et al. reported asymmetric direct-type aldol reaction catalyzed by calcium-diolate 
complex that was prepared from Ca(HMDS)2(thf)2 and chiral diol.
13  By adding potassium 
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thiocyanate (KSCN) as additive enantioselectivity of the products, 39 was enhanced significantly. 
(Figure 1.9)  
Figure 1.10 Asymmetric Mannich reaction catalyzed by barium biphenolate 
Figure 1.11 Asymmetric reactions catalyzed by chiral barium and strontium alkoxide 
complexes. 
Shibasaki et al. developed chiral biphenol derived barium complex to catalyze asymmetric 
Mannich reaction of imines, 41 with β,γ-unsaturated esters, 42.   The Mannich products formed in 
10 
 
this reaction were isomerized to give aza-Morita-Baylis-Hillman type products, 43 in good 
enantioselectivities.14 (Figure 1.10) 
Shibasaki et al. also discovered a novel chiral diol15 containing phosphine oxide group reacts 
with barium isopropoxide to form chiral complex that catalyze asymmetric Diels-Alder reaction.  
The reaction of siloxydiene, 45 with fumarate, 46 affords 47 with high yield and excellent 
enantioselectivity.  These products are precursor to the synthesis of optically active Tamiflu®.  
They also reported asymmetric cyanation reaction of 49 catalyzed by strontium-diol chiral 
complex, to afford highly enantioselective quaternary carbon centered products, 50. (Figure 1.11) 
1.7 Complexes with chiral phosphoric acid ligands:   
Figure 1.12 Chiral BINOL derived alkaline earth metal phosphate complexes. 
Since the discovery of chiral BINOL phosphoric acid (PA) in 2004 by Terada and Akiyama, 
PA has been emerged as versatile catalyst in many asymmetric transformations yielding highly 
enantioselective products.  Ishihara, first observed calcium complex of BINOL phosphoric acid, 
52c could catalyze asymmetric Mannich reaction of imines with 1, 3-diketones to afford products, 
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57 with high yield and enantioselectivities.16  The catalyst is prepared by treating calcium 
methoxide with two equivalents of chiral BINOL phosphoric acid. (Figure 1.13)  
 
Figure 1.13 Asymmetric Mannich reaction catalyzed by calcium-BINOL phosphate 
complex. 
 
Figure 1.14 Asymmetric reactions catalyzed by calcium-VAPOL phosphate complexes. 
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Figure 1.15 Asymmetric synthesis of aziridines. 
Figure 1.16 Asymmetric phosphination, Diels-Alder and hetero-Diels-Alder reactions 
catalyzed by metal-BINOL phosphate complexes. 
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Antilla et al. developed alkaline earth metal VAPOL phosphate complexes to efficiently 
catalyze asymmetric benzoyloxylation, chlorination and Michael reactions of 3-substituted 
oxindoles (Figure 1.14) and also asymmetric synthesis of aziridines to give highly enantioselective 
products (Figure 1.15).17  They also reported asymmetric catalytic reaction of chiral BINOL 
phosphate metal complexes applied to asymmetric phosphination of imines.  Recently, they 
reported an elegant asymmetric Diels-Alder reaction and hetero-Diels-Alder reaction using 
Danishefsky’s diene forming highly enantioselective and diastereoselective spirocyclic 
compounds in excellent yields. (Figure 1.16)  
 
Figure 1.17 Asymmetric carbonyl-ene reaction and Friedel-Crafts reaction catalyzed by  
calcium-BINOL phosphate complex  
 
Rueping et al. reported calcium-BINOL phosphate complex activation of diketoesters in 
asymmetric carbonyl-ene reaction and also in the Friedel-Crafts reaction of indoles to afford highly 
enantioselective quaternary hydroxyesters 79, 81 in excellent yields.18 (Figure 1.17) Masson 
reported efficient asymmetric bromination of enecarbamates catalyzed by calcium-BINOL 
phosphate complex using NBS in good yields and excellent enantioselectivities.  Using similar 
catalyst they recently showed asymmetric addition of enamides to azodicarboxylates, two different 
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products were isolated by changing the workup procedure in high yields and excellent 
enantioselectivities.19 (Figure 1.18)  
 
Figure 1.18 Calcium-BINOL phosphate catalyzed asymmetric amination reactions 
1.8 Complexes with chiral Bisoxazoline (Box) ligands: 
 
Figure 1.19 Chiral bisoxazoline-calcium complexes: 
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Figure 1.20 Chiral Box-calcium complexes catalyzed asymmetric 1,4-addition and [3+2] 
cycloaddition reactions. 
Kobayashi et al. first developed calcium complexes of chiral bisoxazoline (Box) ligands.  
Calcium alkoxide or amide deprotonates the acidic hydrogen of the methylene group tethering 
oxazolines forming an anionic bidentate complex that has rigid chiral environment.  In these 
complexes the metal center acts as mild Lewis acidic site that helps in the coordination of the 
ligand and the Brønsted basicity of the overall complex can be controlled by changing the free 
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counterion.  They reported an efficient asymmetric 1, 4-addition of Schiff bases of glycine 
derivatives, 93 with α, β-unsaturated esters, 92 for the synthesis of 4-substituted, 94 and 3-
substituted, 97 glutamic acid derivatives in excellent enantioselectivities and diastereoselectivities.  
For 3-substituted glutamic acid derivatives, the [3+2]-cylcoadduct was observed as major side 
product.  They circumvent this problem by using tert-butyl phenylmethylene group Schiff base of 
α-aminoester, 96 to get highly regioselective 1, 4-addition product.  They further reported the 
asymmetric [3+2] cycloaddition reactions with high yields and excellent stereoselectivities.20 
(Figure 1.20) 
Kobayashi et al. have also reported similar Box-type ligand prepared from calcium chloride, 
and an external base.  For this catalyst system, to improve the acidity of hydrongen on the 
methylene group, cyano group was introduced and 1,1,3,3-tetramethylguanidine (TMG) was used 
as external base.  They showed this catalyst system also effectively catalyzes asymmetric 1, 4-
addition and [3+2] cycloaddition reactions in high regio and stereoselectivities.21 (Figure 1.21) 
 
Figure 1.21 Asymmetric 1,4-addition and [3+2] cycloaddition reactions 
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1.9 Complexes with chiral Pyridine Bisoxazoline (Pybox) ligands: 
Figure 1.22 Chiral Calcium-Pybox complexes. 
 
Figure 1.23 Calcium-Pybox catalyzed asymmetric 1,4-addition and Mannich reactions. 
18 
 
Kobayashi et al. has developed a novel stable complex prepared from calcium alkoxide and 
and a neutral coordinative ligand.  Pyridinebisoxazoline (Pybox) is a versatile ligand with three 
nitrogen atoms coordinating to a Lewis acidic metal through coordinative bonds forming a stable 
complex and also providing chiral environment.  They reported efficient asymmetric 1, 4-addition 
reactions of malonates to nitroalkenes and also acrylates catalyzed by chiral calcium-Pybox 
complex.  The enantioselective of the reactions was enhanced in presence of aryl alcohol additive, 
which was presumed because of the steric bulkiness of calcium aryloxide formed.  They also 
reported asymmetric Mannich reaction of malonates to imines with good enantioselectivities.22 
(Figure 1.23)  
Kobayashi et al. have further reported the application of Pybox-Calcium halide complexes in 
asymmetric catalytic 1,4-addition reactions and Mannich reactions to furnish products in good 
yields and excellent enantioselectivities.23 
 
Figure 1.24 Asymmetric 1,4-addition and Mannich reactions 
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1.10 Conclusion:  
To conclude, recent asymmetric transformations catalyzed by chiral alkaline earth methal 
complexes have been summarized in this chapter.  Alkaline earth metals have unique 
characteristics and have got increased attention due to their abundance, less toxicity, Brønsted 
basicity and mild Lewis acidity.  The research in our lab is to focus on using alkaline earth metal 
phosphate complexes of chiral BINOL derivatives to develop enantioselective reactions and the 
results are shown in the next three chapters. 
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2 Asymmetric One-Pot Synthesis of 1, 3-Oxazolidines and 1, 3-Oxazinanes via 
Hemiaminal Intermediates 
 
Note to the Reader: This chapter (Pages 22-54) has been previously published in Organic 
Letters journal with citation Org. Lett., 2014, 16 (16), pp 4098–4101.  DOI: 10.1021/ol501789c 
2.1 Introduction 
Heterocyclic compounds are the cyclic compounds containing N, O, S etc. as part of the ring 
system.  These compounds present in many natural products and exhibit a wide range of properties 
such as antibacterial, antiviral, anti-inflammatory, antimalarial, etc.  More than 50% of the 
pharmaceutical compounds contain heterocyclic compounds in their structural unit.  1, 3-
oxazolidines are a type of heterocyclic compounds which contain nitrogen and oxygen in a 5-
membered cyclic ring.   Chiral 1, 3-oxazolidines are key structural motifs that are present in many 
biologically active compounds and natural products.1  Polycyclic tetrahydroisoquinoline alkaloids 
such as Quinocarcin, 1 and Terazomine, 2 containing 1, 3-oxazolidine group exhibit antitumor 
activities.2 (Figure 2.1) 
 
Figure 2.1 Polycyclic tetrahydroisoquinoline alkaloids. 
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2.2 1, 3-oxazolidines as chiral auxiliaries: 
 Chiral 1, 3-oxazolidine moieties are also applied in asymmetric synthesis as chiral auxiliaries 
in many asymmetric transformations and as chiral ligands in asymmetric catalysis.3  Some 
representative examples4 Aldol reaction, Diels-Alder reaction and Grignard reaction in which 1, 
3-oxazolidines act as chiral auxiliaries to yield highly diastereoselective products were shown in 
Figure 2.2.  They were also used as precursors in synthesis of many key intermediates and natural 
products.
 
Figure 2.2 Reactions with 1, 3-oxazolidines as chiral auxiliaries. 
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2.3 1, 3-oxazolidines as chiral ligands in asymmetric reactions: 
 
Figure 2.3 Chiral 1, 3-oxazolidine ligands  
 
Figure 2.4 Asymmetric allylic alkylation and Diels-Alder reactions. 
Chiral 1, 3-oxazolidines have also been used as ligands (Figure 2.3) in several asymmetric 
reactions.  Asymmetric alkylation, alkynylation of aldehydes and ketones with organozinc 
compounds were first reported with excellent enantioselectivities.  Pyridinyloxazolidines, 13a, and 
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phosphino-oxazolidines, 13b-c, showed great utility as bidentate ligands in palladium-catalyzed 
asymmetric reactions with high yields and excellent enantioselectivities.5 (Figure 2.4) 
2.4 Synthesis of chiral 1, 3-oxazolidines: 
2.4.1 Stereospecific synthetic methods:  
Several methods have been reported for the synthesis of chiral 1, 3-oxazolidines owing to their 
growing importance in synthetic chemistry.  The classical method for the preparation of these 
compounds is the condensation of chiral aminoalcohols with carbonyl compounds such as 
aldehydes or ketones.  Starting from a variety of readily available chiral aminoalcohols, this 
method provides access to number of chiral oxazolidines. (Figure 2.5) 
 
Figure 2.5 Condensation of chiral aminoalcohols with aldehydes and ketones. 
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Figure 2.6 Double Michael addition reaction. 
In 2007, Kwon et al. developed asymmetric synthesis of oxazolidines by the asymmetric 
double Michael addition reaction of aminoalcohols to electron-deficient alkynes catalyzed by 
bisphosphine.6  They described that the intermediate phosphonium ion formed after first Michael 
addition was stabilized due to the presence of addition phosphine is bis(diphenylphosphine) 
derivative which led to the formation of oxazolidine product, 29 in high yields. 
 
Figure 2.7 Formal cycloaddition of vinyl epoxides with imines. 
Jarvo et al. reported the stereospecific synthesis of chiral oxazolidines by rhodium catalyzed 
the formal cycloaddition of vinyl epoxides with imines, by controlling the rates of isomerization 
of allylmetal intermediates.  Starting with (R)-vinyl epoxide the reaction provides 32 with good 
yield and excellent enantioselectivity with the retention at stereogenic center from vinyl epoxide.7 
(Figure 2.7) 
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2.4.2 Stereoselective synthetic methods:  
Figure 2.8 Asymmetric oxyamination and formal cycloaddition reactions for stereoselective 
synthesis of chiral oxazolidines.  
Yoon and co-workers reported the first enantioselective oxyamination of olefins catalyzed by 
chiral iron(II) bis(oxazoline) complex.8  They proposed the reaction proceeds through a kinetic 
resolution pathway in which one enantiomer of the racemic oxaziridine, 34 reacts first to form 
high diastereoselective and enantioselective products, 35.  Jarvo et. al. reported the first catalytic 
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asymmetric synthesis of 1, 3-oxazolidines, by the palladium formal cycloaddition reaction of 
racemic vinyl epoxides with imines which proceeds through a dynamic kinetic resolution to yield 
products with high yields and good enantioselectivities7.  Du et al. have also reported asymmetric 
formal cycloadditions of vinyl epoxide with imines catalyzed by rhodium with chiral sulfur/alkene 
ligand.  This reaction also follows dynamic kinetic resolution process and they further applied this 
methodology to isatin imines, 40 to get highly enantioselective spirooxindole oxazolidines, 41 in 
good yields.9  
2.5 Chiral BINOL phosphoric acids and alkaline earth metal phosphates: 
 
Figure 2.9 Chiral phosphoric acids. 
Over the last decade, chiral BINOL phosphoric acid has been emerged as one of the privileged 
hydrogen-bond donor catalysts in many asymmetric transformations.10  The pKa of BINOL 
phosphoric acid is ranging 3 to 6 in DMSO,11 which exhibit considerable acidity to activate 
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substrates through hydrogen bonding.  BINOL phosphoric acids are considered to be strong 
Brønsted acids that activate electrophiles by protonation and lowering the LUMO to react with the 
nucleophile.  With the chiral BINOL backbone and varying the steric groups on 3 and 3’ positions, 
the chiral environment can be controlled.   
 
Figure 2.10 General synthetic scheme for the preparation of chiral BINOL phosphoric 
acid. 
The versatility of these catalysts has been attributed to many features such as the strong 
Brønsted acidity of (-OH), Lewis acidity of oxygen, steric controlling groups at 3, 3’ positions and 
mild reaction conditions for plethora of asymmetric reactions to yield excellent enantioselective 
products.  Different structural variants of chiral phosphoric acids have been developed over the 
years and are applied to afford a wide range of highly enantioselective products.  The general 
method for the synthesis of BINOL phosphoric acids is shown below. (Figure 2.10)  The 
bromination of protected chiral BINOL, 44 with nBuLi and Br2 gives 45.  Based on the steric 
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groups on 3, 3’ positions, 45 is subjected to Suzuki coupling or Kumada coupling to form 46.  
Deprotection followed by phosphorylation yields chiral BINOL phosphoric acid 48.  
The application of chiral phosphoric acids was first reported in 1971 as chiral resolving agents 
for amines.12  In 2004, Akiyama and Terada independently discovered catalytic asymmetric 
Mannich reactions catalyzed by chiral BINOL phosphoric acid.13  The authors proposed the dual 
activation of imine and nucleophile with chiral phosphoric acid through hydrogen bonding 
yielding products with high enantioselectivity.  Since then, several research groups has focused on 
development of tremendous asymmetric reactions catalyzed by chiral phosphoric acid. 
Figure 2.11 Asymmetric Mannich reactions catalyzed by chiral BINOL phosphoric acid. 
In 2010, Ishihara et. al. first discovered the metal contaminants while column chromatography 
purification of BINOL phosphoric acid.  They reported that the metal contaminants present in the 
silica gel could replace the hydrogen in phosphoric acid –OH forming phosphate metal salts.  
Optimization of the reaction conditions with various BINOL metal phosphates, they showed that 
Calcium salt of phosphoric acid was the real catalyst to give 54 with 92% ee whereas pure acid of 
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BINOL phosphoric acid that was washed with 6N HCl gave only 27% ee.  Later, List14 also 
confirmed this by comparing ICP-OES trace element analysis of BINOL phosphoric acid washed 
with HCl (Batch B) and another compound that was purified after column (Batch A).  The data 
clearly shows the metal contamination for the compound purified after column chromatography 
(Table 2.2) 
Table 2.1 Optimization to find real catalyst: 
  
Table 2.2. Trace Element Analysis by ICP-OES. (Values in ppm) 
Batch Na K Mg Ca Al Si Fe Pd Zn 
A 6151 29 3590 7482 <5 560 15 7 5 
B 16 13 20 83 20 725 9 <5 <5 
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Since this discovery, research groups have developed many metal complexes of BINOL 
phosphoric acid with Ca, Mg, Sr, Ba, Pd, Au, Sc, Ir, Cu, Ag, etc.10g  Research in our group also 
focused on developing novel asymmetric reactions catalyzed by BINOL phosphoric acid and 
phosphate metal complexes.  In particular, we are interested in catalytic asymmetric reactions of 
alkaline earth metal phosphate complexes.  Compared to BINOL phosphoric acid, chiral BINOL 
phosphate complexes have advantages such as mild Lewis acidic site at the metal, Lewis basic site 
arising from P=O oxygen, and strong Brønsted basicity of the counterion owing to the low 
electronegativity of metal ions and multiple coordination sites due to large ionic radius of the 
metal.  For selected reactions of chiral BINOL alkaline earth metal phosphate complexes see 
Chapter 1, Section 1.7. 
 
Figure 2.12 Chiral BINOL metal phosphate complex. 
2.6 Asymmetric one-pot synthesis of 1, 3-oxazolidines: 
In 2008, our group disclosed enantioselective synthesis of chiral N,O-aminals by the 
asymmetric addition of alcohols to imines catalyzed by 3,3’-9-anthryl derived chiral BINOL 
phosphoric acid catalyst.15 (Figure 2.13)  We envisioned to further apply this methodology for the 
asymmetric synthesis of chiral 1, 3-oxazolidines.  We hypothesized, the hemiaminal intermediate 
obtained after initial alcohol addition to imines would undergo intramolecular cyclization through 
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nucleophilic substitution in 5-exo-tet manner, following the Baldwin’s rules16. (Figure 2.14)  
Baldwin in 1976, reported some rules for the ring closure of organic compounds.  These rules are 
designed based on the stereochemical requirements of the transition states for the ring closure of 
tetrahedral, trigonal, and diagonal carbons.  Based on Baldwin rules 5-exo-tet ring closures is 
favored.  In this case, since halogen is the leaving group, the geometry of the carbon bearing 
halogen is tetrahedral (tet), the number of atoms in the skeleton is 5 and the breaking of bond is 
exocyclic, so we propose this reaction will undergo ring closure in 5-exo-tet pathway. 
 
Figure 2.13 Enantioselective addition of alcohols to imines. 
 
Figure 2.14 Retrosynthetic pathway. 
34 
 
2.7 Optimization of reaction conditions:  
Table 2.3 Optimization of reaction conditions for alcohol addition to imines. 
 
Inspired by the results of Ishihara and List, we started our investigation to find the real catalyst 
for the enantioselective addition of alcohols to imines.  Interestingly, 9-anthryl derived BINOL 
phosphoric acid, P2 afforded product 3a with negligible enantioselectivity (Table 2.2, entry 
1).This paved way for us to explore different alkali and alkaline earth metal BINOL phosphate 
complexes for this reaction.  Ca[P2]2 also gave product with only 10% enatiomericexcess (ee) 
whereas Mg[P2]2 yielded product with high yield and excellent enantioselectivity (Table 2.2, 
entries 2-3).  Upon using 3, 3’-triisopropyl derived BINOL phosphate complexes, we are delighted 
to get product 60a with 97% ee with Mg[P1]2.  Ca, Li, Al, Zn and Sr complexes of BINOL 
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phosphate showed moderate selectivity (Table 2.2, entries 4-9).  Based on the optimization data, 
clearly using Mg[P1]2 in ethyl acetate to imine, 58a and alcohol, 59 at room temperature in 
presence of molecular sieves gave hemiaminal intermediate, 60a in high yield and good 
enantioselectivity. 
Table 2.4 Optimization of base mediated intramolecular cyclization. 
 
A brief screening of bases for the intramolecular cyclization of 60a was performed and we 
observed that K3PO4, DBU, Cs2CO3 in ethyl acetate did not lead to the cyclized product 61a.  By 
using the more reactive substrate 60b with bromide as the leaving group provided the desired 
transformation with bases DBU and KOtBu in good yields.  But the highest enantioselectivity that 
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we observed for the preparation of 60b under the optimized conditions was 65% (Table 2.3, entries 
5, 6).  Interestingly, Cs2CO3 gave product 61a with retention in enantioselectivity and high yield 
(Table 2.3, entry 7).  Cesium salt with its large ionic radius, low degree of solvation and ion-pairing 
provided the balance in the reaction, which is not too strong base and not weak base either.  To 
our delight, upon screening the solvents using 60a, using polar aprotic DMF showed better results 
to get product 61a.  KOtBu showed little reduction in selectivity, whereas Cs2CO3 at 0°C produced 
4a in high yield with retention of selectivity of 93% ee. 
With the idea of combining these two steps to develop a one-pot reaction, we performed the 
intramolecular cyclization of 60a in ethyl acetate using Cs2CO3, but no occurrence of 61a was 
detected.  Alternately, upon the addition of alcohol, 59 to imine, 58a in DMF and Mg[P1]2 afforded 
racemic 60a.  From these observations, to make it one-pot synthesis, we decided to concentrate 
ethyl acetate after enantioselective addition of alcohol to imine and then add DMF and Cs2CO3 at 
0 °C to yield 61a in high yield and retention of high enantioselectivity. 
2.8 Substrate scope for one-pot synthesis of chiral 1, 3-oxazolidines: 
With the optimal conditions in hand, a broad range of chiral 1, 3-oxazolidines were prepared 
in one-pot using different imine substrates.  The results were summarized in Figure 2.15.  
Substrates with both electron-donating and electron-withdrawing groups at para position on the 
phenyl ring of imines had little effect on the enantioselectivity.  Electron-withdrawing group at the 
meta position on the phenyl ring (61d) showed excellent enantioselectivity compared to electron-
releasing methyl group (61i).  Ortho substituted –CH3 group (61h) showed higher selectivity 
compared to meta (61i).  This is attributed to different steric factors.  The absolute configuration 
for all substrates was assigned in correlation with the HPLC data comparison of the product 60a 
that was reported in literature. 
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Figure 2.15 Substrate scope for chiral 1, 3-oxazolidines. 
2.9 Asymmetric one-pot synthesis of 1, 3-oxazinanes: 
Based on the reaction design, we envisaged the possible synthesis of chiral 1, 3-oxazinanes17 
using this methodology.  The intramolecular cyclization would undergo in 6-exo-tet fashion which 
38 
 
is favored according to Baldwin’s rules.  Mg[P1]2 catalyzed the addition of 3-chloropropanol, 62a 
and 3-bromopropanol, 62b to imines 58 with high enantioselectivity. (Table 2.4) 
Table 2.5 Optimization of reaction conditions. 
 
Table 2.6 Optimization for base mediated intramolecular cyclization. 
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For intramolecular cyclization in presence of Cs2CO3 base, slight drop in enantioselectivity 
was observed when chlorine was the leaving group (Table 2.5, entries 1, 2).  We assumed because 
of the long reaction time in this case, the starting material or product is losing selectivity in basic 
medium.  By changing the leaving group to better leaving group bromine, the reaction completes 
in 2 h by retaining the enantioselectivity (Table 2.5, entries 3, 4).  
2.10 Substrate scope for one-pot synthesis of chiral 1, 3-oxazinanes: 
 
Figure 2.16 Substrate scope for one-pot synthesis of chiral 1, 3-oxazinanes. 
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With the optimized conditions, we synthesized substrates of chiral 1, 3-oxazinanes with 
different substituents on the phenyl group in high yields and good enantioselectivities. 
2.11 Conclusion:  
To summarize, we have developed a highly efficient 3, 3’-triisopropyl BINOL magnesium 
phosphate catalyzed one-pot synthesis of chiral 1, 3-oxazolidines and chiral 1, 3-oxazinanes.  The 
products are formed with good enantioselectivities by the base mediated intramolecular 5-exo-tet 
and 6-exo-tet cyclization of hemiaminal intermediates formed by the enantioselective addition of 
alcohols to imines. 
2.12 Experimental data: 
General considerations: 
All reactions were carried out in flame-dried screw-cap test tubes with magnetic stirring.  Ethyl 
acetate was dried over 4Å MS.  Anhydrous N, N-dimethylformamide was purchased from 
commercial sources and transferred under Argon atmosphere.  Alcohols were obtained 
commercially and purified under standard methods or dried over 4Å MS before use.  Chiral (R)-
BINOL was purchased from commercial sources and used without further purification.  
Substituted BINOL phosphoric acids H(P1),18 H(P2)19 were synthesized according to the literature 
procedures.  Ca(P1)2,
20 Mg(P1)2
21 were prepared as the reported procedures.  Thin layer 
chromatography was performed on Merck TLC plates (silica gel 60 F254).  Flash column 
chromatography was performed with Merck silica gel (230-400 mesh).  Enantiomeric excess (ee) 
was determined using a Varian Prostar HPLC with a 210 binary pump and a 335 diode array 
detector.  Optical rotations were performed on a Rudolph Research Analytical Autopol IV 
polarimeter (λ 589) using a 700-μL cell with a path length of 1-dm.  1HNMR and 13C NMR were 
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recorded on Varian Inova-400 spectrometer with chemical shifts reported relative to 
tetramethylsilane (TMS).  31PNMR was recorded on a Varian Inova-400 instrument with H3PO4 
as an external standard.  The HRMS data were measured on an Agilent 1100 LC/MS ESI/TOF 
mass spectrometer with electro-spray ionization.  Compounds described in the literature were 
characterized by comparing their spectral data to the reported values. 
Preparation of Catalyst, M[P1]n:21 
M[P1]n (M = Ca, Mg, Li, Al, Zn, Sr) were prepared by adding ‘H[P1] washed with HCl’ (10 
mol%) and Ca(OMe)2 (5 mol%) or Mg(OtBu)2 (5 mol%) or Li(OiPr) (10 mol%) or Al(OiPr)3 (0.33 
mol%) or Zn(OMe)2  (5 mol%) or Sr(OiPr)2 (5 mol%) into a flame dried reaction tube.  Evacuate 
the tube and filled with Argon three times.  Added 1 ml of dry dichloromethane and 1 ml of 
anhydrous methanol to the reaction tube.  Stirred the reaction mixture at room temperature for 1 
h.  Solvent was concentrated, added 1 ml dichloromethane and concentrated again under reduced 
pressure to obtain the catalyst as pale yellow solid. 
Mg[P1]2 Spectral data: 
1H NMR (400MHz, DMSO): δ 7.96 (d, J = 7.9 Hz, 2H), 7.75 (s, 2H), 7.37 (t, J = 7.4 Hz, 2H), 
7.25 (t, J = 7.5 Hz, 2H), 7.03 (m, 6H), 3.15 (d, J = 5.0 Hz, 1H), 3.00 – 2.85 (m, 3H), 2.63 – 2.51 
(m, 2H), 1.26 (d, J = 6.7 Hz, 12H), 1.15 (d, J = 3.6 Hz, 12H), 1.06 (d, J = 6.7 Hz, 6H), 0.85 (d, J 
= 6.7 Hz, 6H).     31P (400MHz, DMSO): δ 3.39.  MS (MALDI) Calcd for C100H112MgO8P2 
([M+H]+) m/z   1527.77 Found 1527.96. 
N-Acyl imines (1a-k) were synthesized according to the literature procedure and purified by 
sublimation.22   
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General procedure for the preparation of chiral 1,3-Oxazolidines: 
To a flame-dried reaction tube charged with 4Å molecular sieves 50mg (pre-activated in oven) 
was added N-benzoyl imine 58 (0.2 mmol), catalyst Mg[P1]2 (0.005 mmol), the tube was 
evacuated and filled with argon.  Added anhydrous toluene (1.0 ml) followed by 2-chloro ethanol 
59 (0.4 mmol) via oven-dried syringe to the reaction mixture.  The reaction was stirred at room 
temperature for 24h.  The completion of reaction was monitored by TLC and toluene (1.0 ml) was 
removed by rotovap.  Added anhydrous dimethyl formamide to the reaction tube and cooled to 0 
°C.  Added Cs2CO3 (0.4 mmol) and the solution was allowed to stir at room temperature for 4h.  
The crude product was purified by flash column chromatography (ethyl acetate : hexane) to get 
the pure 1, 3-oxazolidine product 61 and the enantiomeric excess was determined by chiral HPLC 
analysis. 
(R)-phenyl(2-phenyloxazolidin-3-yl)methanone23 
The product was obtained by flash column chromatography as viscous oil(hexane : ethyl 
acetate, 1:1) 92% yield, 93% ee. HPLC Analysis: Chiralcel AD-H (hexane:iPrOH = 80:20, 1.0 
mL/min), t r-major 9.36 min, t r-minor 15.53 min.  [α]20D= +140.7° (c =1.85, CHCl3).  1H NMR 
(400MHz, CDCl3): δ 3.50-4.50 (bm, 4H), 6.0 (bs, 1st rotamer), 6.5 (bs, 2nd rotamer), 7.2-8.0 (bm, 
10H). 13C NMR (400MHz, CDCl3): δ 48.31(broad peak), 66.66(broad peak), 89.35(broad peak), 
126.70, 127.55, 128.30, 128.44, 128.80, 130.71, 135.80, 138.59, 169.58ppm. HRMS (ESI) calcd 
for C16H15NO2 ([M+H]
+) m/z 254.1103, found 254.1186. 
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 (R)-(2-bromophenyl)oxazolidin-3-yl)(phenyl)methanone 
The product was obtained by flash column chromatography as viscous oil(hexane : ethyl 
acetate, 1:1) 99% yield, 93% ee. HPLC Analysis: Chiralcel AD-H (hexane:iPrOH = 80:20, 1.0 
mL/min), t r-major 11.72 min, t r-minor 14.71 min.  [α]20D= +162.5° (c =2.25, CHCl3).    1H NMR 
(400MHz, CDCl3): δ 3.50-4.50 (bm, 4H), 6.1 (bs, 1st rotamer), 6.5 (bs, 2nd rotamer), 7.2-8.0 (bm, 
9H).  13C NMR (400MHz, CDCl3): δ 48.20(broad peak), 66.82(broad peak), 88.91(broad peak), 
122.88, 127.54, 130.90, 135.53, 137.71, 169.59ppm.  HRMS (ESI) calcd for C16H14BrNO2 
([M+H]+) m/z 332.0208, found 332.0285. 
 (R)-(2-(4-fluorophenyl)oxazolidin-3-yl)(phenyl)methanone 
The product was obtained by flash column chromatography as viscous oil(hexane : ethyl 
acetate, 1:1) 93% yield, 90% ee.  HPLC Analysis: Chiralcel AD-H (hexane:iPrOH = 80:20, 1.0 
mL/min), t r-major 9.80 min, t r-minor 14.04 min.  [α]20D= +162.2° (c =2.15, CHCl3).   1H NMR 
(400MHz, CDCl3): δ 3.50-4.50 (bm, 4H), 6.1 (bs, 1st rotamer), 6.5 (bs, 2nd rotamer), 6.9-7.9 (bm, 
9H).  13C NMR (400MHz, CDCl3): δ 48.42(broad peak), 66.87(broad peak), 89.12(broad peak), 
115.43, 115.65, 127.77, 128.56, 128.82, 128.91, 134.72, 135.85, 161.91, 164.37, 169.78ppm.  
HRMS (ESI) calcd for C16H14FNO2 ([M+H]
+) m/z 272.1009, found 272.1090. 
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 (R)-(2-(3-fluorophenyl)oxazolidin-3-yl)(phenyl)methanone 
The product was obtained by flash column chromatography as viscous oil(hexane : ethyl 
acetate, 1:1) 94% yield, 97% ee.  HPLC Analysis: Chiralcel AD-H (hexane:iPrOH = 90:10, 1.0 
mL/min), t r-major 18.43 min, t r-minor 24.52 min.  [α]20D= +154.6° (c =1.25, CHCl3). 1H NMR 
(400MHz, CDCl3):  δ 3.50-4.50 (bm, 4H), 6.5(bs, 1H), 7.3-7.8 (bm, 9H).  13C NMR (400MHz, 
CDCl3): δ 47.35(broad peak), 65.75(broad peak), 88.17(broad peak), 126.70, 127.41, 127.56, 
127.81, 130.07, 133.84, 134.75, 136.38, 168.80.  HRMS (ESI) calcd for C16H14FNO2 ([M+H]
+) 
m/z 272.1009, found 272.1087. 
 (R)-(2-(4-Chlorophenyl)oxazolidin-3-yl)(phenyl)methanone 
The product was obtained by flash column chromatography as viscous oil(hexane : ethyl 
acetate, 1:1) 94% yield, 95% ee.  HPLC Analysis: Chiralcel AD-H (hexane:iPrOH = 90:10, 1.0 
mL/min), t r-major 13.65 min, t r-minor 21.19 min.  [α]20D= +173.9° (c =1.3, CHCl3).    1H NMR 
(400MHz, CDCl3): δ 3.50-4.40 (bm, 4H), 6.20-6.75 (bs, 1H), 6.8-8.0 (bm, 9H).  13C NMR 
(400MHz, CDCl3): δ 48.20(broad peak), 66.76(broad peak), 88.62(broad peak), 113.57, 113.79, 
115.62, 115.83, 122.49, 122.51, 127.55, 128.36, 129.99, 130.07, 130.88, 161.57, 164.02, 169.64. 
HRMS (ESI) calcd for C16H14ClNO2 ([M+H]
+) m/z 288.0713, found 288.0794. 
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(R)-phenyl(2-(4-(trifluoromethyl)phenyl)oxazolidin-3-yl)methanone 
The product was obtained by flash column chromatography as viscous oil(hexane : ethyl 
acetate, 1:1) 94% yield, 97% ee.  HPLC Analysis: Chiralcel AD-H (hexane:iPrOH = 95:05, 1.0 
mL/min), t r-major 25.23 min, t r-minor 26.96 min.  [α]20D= +152.4° (c =1.2, CHCl3).  1H NMR 
(400MHz, CDCl3): δ 3.50-4.50 (bm, 4H), 6.20-6.75 (bs, 1H), 7.2-8.0 (bm, 9H).  13C NMR 
(400MHz, CDCl3):  δ 48.21(broad peak), 66.89(broad peak), 88.73(broad peak), 125.39, 127.22, 
127.55, 128.41, 131, 135.34, 142.52, 169.71ppm.  HRMS (ESI) calcd for C17H14F3NO2 ([M+H]
+) 
m/z 322.0977, found 322.1058. 
 (R)-phenyl(2-(p-tolyl)oxazolidin-3-yl)methanone 
The product was obtained by flash column chromatography as viscous oil(hexane : ethyl 
acetate, 1:1) 97% yield, 90% ee.  HPLC Analysis: Chiralcel AD-H (hexane:iPrOH = 85:15, 1.0 
mL/min), t r-major 13.32 min, t r-minor 17.56 min.  [α]20D= +104.3° (c =1.0, CHCl3).  1H NMR 
(400MHz, CDCl3): δ 2.33(s, 3H), 3.50-4.50 (bm, 4H), 6.1 (bs, 1st rotamer), 6.5 (bs, 2nd rotamer), 
7.0-7.9 (bm, 9H).  13C NMR (400MHz, CDCl3):  δ 21.19, 48.35(broad peak), 66.57(broad peak), 
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89.35(broad peak), 126.59, 127.51, 128.25, 129.12, 130.63, 135.62, 135.86, 138.61, 169.45ppm.  
HRMS (ESI) calcd for C17H17NO2 ([M+H]
+) m/z 268.1259, found 268.1336. 
 (R)-phenyl(2-(o-tolyl)oxazolidi-3-yl)methanone 
The product was obtained by flash column chromatography as viscous oil(hexane : ethyl 
acetate, 1:1) 98% yield, 96% ee.  HPLC Analysis: Chiralcel AD-H (hexane:iPrOH = 80:20, 1.0 
mL/min), t r-major 8.27 min, t r-minor 10.72 min.  [α]20D= +78.151° (c =1.8, CHCl3).  1H NMR 
(400MHz, CDCl3): δ 2.0-2.7(bm, 3H), 3.50-4.50 (bm, 4H), 6.0-6.4 (bs, 1st rotamer), 6.4-6.8 (bs, 
2nd rotamer), 7.0-7.9 (bm, 9H).  13C NMR (400MHz, CDCl3): δ  18.95, 45.17(broad peak, 1st 
rotomer), 48.95(broad peak, 2nd rotomer), 63.9(broad peak, 1st rotomer), 66.5(broad peak, 2nd 
rotomer), 88.02(broad peak), 125.85, 127.62, 128.28, 128.84, 130.95, 135.84, 136.88, 169.44  
HRMS (ESI) calcd for C17H17NO2 ([M+H]
+) m/z 268.1259, found 268.1336. 
(R)-phenyl(2-(m-tolyl)oxazolidi-3-yl)methanone 
The product was obtained by flash column chromatography as viscous oil(hexane : ethyl 
acetate, 1:1) 96% yield, 83% ee.  HPLC Analysis: Chiralcel AD-H (hexane:iPrOH = 80:20, 1.0 
mL/min), t r-major 7.60 min, t r-minor 10.03 min.  [α]20D= +103.7° (c =1.05, CHCl3).  1H NMR 
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(400MHz, CDCl3): δ 2.33(s, 3H), 3.50-4.50 (bm, 4H), 5.8-6.3 (bs, 1st rotamer), 6.3-6.75 (bs, 2nd 
rotamer), 7.0-7.9 (bm, 9H)  13C NMR (400MHz, CDCl3): δ 21.42, 48.38(broad peak), 66.62(broad 
peak), 89.39(broad peak), 123.67, 127.35, 128.26, 129.58, 135.82, 138.12, 138.46, 169.51.  HRMS 
(ESI) calcd for C17H17NO2 ([M+H]
+) m/z 268.1259, found 268.1329. 
(R)-(2-(naphthalen-1-yl)oxazolidin-3-yl)(phenyl)methanone 
The product was obtained by flash column chromatography as viscous oil(hexane : ethyl 
acetate, 1:1) 94% yield, 96% ee.  HPLC Analysis: Chiralcel OD-H (hexane:iPrOH = 90:10, 1.0 
mL/min), t r-minor 22.39 min, t r-major 32.33 min.  [α]20D= -3.75° (c =1.9, CHCl3).  1H NMR (400MHz, 
CDCl3):  δ 3.50-4.50 (bm, 4H), 6.4-6.8(bm, 1H), 7.25-8.0 (bm, 12H).  13C NMR (400MHz, 
CDCl3):  δ(major rotamer) 48.63(broad peak), 66.44(broad peak), 89.12(broad peak), 124.07, 
124.78, 125.95, 126.45, 128.37, 128.46, 128.62, 129.77, 130.79, 132.84, 134.13, 135.73, 170.01.  
HRMS (ESI) calcd for C20H17NO2 ([M+H]
+) m/z 304.1259, found 304.1342. 
General procedure for the synthesis of chiral 1,3-Oxazinanes: 
1,3-Oxazinanes were prepared according to the same procedure as  described for the synthesis 
of chiral 1,3-Oxazolidines.  
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Analytical data: 
   (R)-phenyl(2-phenyl-1,3-oxazinan-3-yl)methanone 
The product was obtained by flash column chromatography as viscous oil(hexane : ethyl 
acetate, 1:1) 92% yield, 95% ee.  HPLC Analysis: Chiralcel AD-H (hexane:iPrOH = 85:15, 1.0 
mL/min), t r-major 8.68 min, t r-minor 14.71 min.  [α]20D= +133.75° (c =0.45, CHCl3).  1H NMR 
(400MHz, CDCl3):  δ 1.39-1.46(m, 1H), 1.9-2.2(m, 1H), 3.0-3.25(m, 1H), 3.7-3.9(m, 2H), 4.45(br, 
1H), 6.5(br, 1H), 7.3-7.7(m, 10H).  13C NMR (400MHz, CDCl3): δ 25.95, 37.54(broad peak), 
60.86, 84.10(broad peak), 126.98, 127.02, 128.26, 128.65, 129.14, 130.21, 135.29, 136.21, 171.59.  
HRMS (ESI) calcd for C17H17NO2 ([M+H]
+) m/z 268.1332, found 268.1336. 
 (R)-(2-(3-fluorophenyl)-1,3-oxazinan-3-yl)(phenyl)methanone 
The product was obtained by flash column chromatography as viscous oil(hexane : ethyl 
acetate, 1:1) 93% yield, 95% ee.  HPLC Analysis: Chiralcel AD-H (hexane:iPrOH = 85:15, 1.0 
mL/min), t r-major 9.44 min, t r-minor 19.63 min.  [α]20D= +103.7° (c =1.8, CHCl3).  1H NMR (400MHz, 
CDCl3):  δ 1.36-1.48(m, 1H), 1.9-2.2(m, 1H), 3.0-3.25(m, 1H), 3.7-3.9(m, 2H), 4.45(br, 1H), 
6.5(br, 1H), 7.3-7.7(m, 9H).  13C NMR (400MHz, CDCl3):  δ 24.99, 37.33(broad peak), 60.02, 
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82.48(broad peak), 126.07, 127.65, 127.82, 128.47, 129.47, 133.42, 133.99, 134.20, 170.66.  
HRMS (ESI) calcd for C17H16FNO2 ([M+H]
+) m/z 286.1165, found. 
 
 
(R)-(2-(4-fluorophenyl)-1,3-oxazinan-3-yl)(phenyl)methanone 
The product was obtained by flash column chromatography as viscous oil(hexane : ethyl 
acetate, 1:1) 96% yield, 91% ee.  HPLC Analysis: Chiralcel AD-H (hexane:iPrOH = 90:10, 1.0 
mL/min), t r-major 12.40 min, t r-minor 21.65 min.  [α]20D= +91.09° (c =2.1, CHCl3). 1H NMR 
(400MHz, CDCl3):  δ 1.36-1.48(m, 1H), 1.9-2.2(m, 1H), 3.0-3.25(m, 1H), 3.7-3.9(m, 2H), 4.45(br, 
1H), 6.5(br, 1H), 7.05-7.20(m, 2H), 7.3-7.6(m, 7H).  13C NMR (400MHz, CDCl3):  δ 25.89, 
38.17(broad peak), 60.75, 83.34(broad peak), 115.90, 116.25, 126.85, 127.01, 128.78, 130.30, 
135.15, 160.70, 164.63, 171.53.  HRMS (ESI) calcd for C17H16FNO2 ([M+H]
+) m/z 286.1238, 
found 286.1246. 
 
(R)-(2-(4-bromophenyl)-1,3-oxazinan-3-yl)(phenyl)methanone 
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The product was obtained by flash column chromatography as viscous oil(hexane : ethyl 
acetate, 1:1) 91% yield, 89% ee.  HPLC Analysis: Chiralcel AD-H (hexane:iPrOH = 85:15, 1.0 
mL/min), t r-major 9.63 min, t r-minor 21.44 min.  [α]20D= +76.7° (c =0.9, CHCl3).  1H NMR (400MHz, 
CDCl3):  δ 1.35-1.5(m, 1H), 1.9-2.2(m, 1H), 3.0-3.25(m, 1H), 3.7-3.9(m, 2H), 4.45(br, 1H), 6.5(br, 
1H), 7.3-7.6(m, 9H).  13C NMR (400MHz, CDCl3):  δ 24.97, 37.17(broad peak), 60.03, 
82.60(broad peak), 121.59, 126.05, 127.82, 127.97, 129.47, 131.43, 134.14, 134.52, 170.66.  
HRMS (ESI) calcd for C17H16BrNO2 ([M+H]
+) m/z 346.0437, found 346.0442. 
 
(R)-phenyl(2-(4-(trifluoromethyl)phenyl)1,3-oxazinan-3-yl)methanone 
The product was obtained by flash column chromatography as viscous oil(hexane : ethyl 
acetate, 1:1) 85% yield, 80% ee.  HPLC Analysis: Chiralcel AD-H (hexane:iPrOH = 85:15, 1.0 
mL/min), t r-major 7.33 min, t r-minor 16.07 min.  [α]20D= +86.46° (c =1.95, CHCl3).  1H NMR 
(400MHz, CDCl3):  δ 1.36-1.48(m, 1H), 1.9-2.2(m, 1H), 3.0-3.25(m, 1H), 3.7-3.9(m, 2H), 4.45(br, 
1H), 6.5(br, 1H), 7.3-7.8(m, 9H).  13C NMR (400MHz, CDCl3):  δ 25.75, 37.69(broad peak), 61.07, 
83.54(broad peak), 122.58, 125.26, 126.11, 127.46, 134.86, 140.53, 171.59.  HRMS (ESI) calcd 
for C18H16F3NO2 ([M+H]
+) m/z 336.1206, found 336.1217. 
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(R)-(2-(4-methoxyphenyl)-1,3-oxazinan-3-yl)(phenyl)methanone 
The product was obtained by flash column chromatography as viscous oil(hexane : ethyl 
acetate, 1:1) 85% yield, 80% ee.  HPLC Analysis: Chiralcel AD-H (hexane:iPrOH = 85:15, 1.0 
mL/min), t r-major 10.71 min, t r-minor 23.20 min.  [α]20D= +100.48° (c =0.45, CHCl3).  1H NMR 
(400MHz, CDCl3):  δ 1.36-1.48(m, 1H), 1.9-2.2(m, 1H), 3.0-3.25(m, 1H), 3.4-3.9(m, 5H), 4.45(br, 
1H), 6.5(br, 1H), 6.7-7.0(m, 2H), 7.3-7.9(m, 7H). 13C NMR (400MHz, CDCl3):  δ 25.98, 
37.84(broad peak), 55.37, 60.60, 84.13(broad peak), 114.49, 126.96, 127.97, 128.30, 128.62, 
135.34, 159.58, 171.50.  HRMS (ESI) calcd for C18H19NO3 ([M+H]
+) m/z 298.1438, found 
298.1454. 
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3 Desymmetrization of 4-substituted cyclohexanones:  Enantioselective synthesis of 
novel axially chiral cyclohexylidene oximes 
3.1 Introduction 
Desymmetrization is the stereochemical modification of a molecule that results in the loss of 
one or more elements of symmetry such as center of inversion, mirror plane or rotational axis.  
One of the major advantages of desymmetrization is the formation of chiral compounds with 
multiple stereocenters from meso or prochiral starting materials in one step.  Recently, 
enantioselective desymmetrization reactions have gained much attention for the synthesis of chiral 
molecules.1  The most common type of desymmetrization reactions are enzyme catalyzed 
transformations.2  Several versatile transition metal catalyzed and non-metal catalyzed 
desymmetrization reactions of meso compounds such as epoxides, anhydrides, diols, aziridines, 
etc have been reported.3   
3.2 Desymmetrization of cyclic ketones:  
Over the last decade, the asymmetric desymmetrization of meso-cyclohexanones has seen 
tremendous progress owing to the formation of contiguous stereocenters on the cylic ring through 
a single transformation.  Since the breakthrough discovery of L-proline catalyzed asymmetric aldol 
reaction by List, Lerner and Barbas in 2000,4 L-proline and its derivatives were used as efficient 
organocatalysts in several key synthetic transformations involving ketones as substrates.  Barbas 
reported elegant synthesis of α-hydroxy ketones through asymmetric desymmetrization of highly 
substituted cyclohexanones via L-proline catalyzed tandem aminoxylation/O-N bond heterolysis.5  
The products are formed with very high enantio- and diastereoselectivities and good yields. (Figure 
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3.1)  In the first step, enamine intermediate generated in situ reacts with nitrosobenzene to form α-
aminoxy ketone, which will react with excess nitrosobenzene, followed by rearrangement affords 
3 with good yield and excellent enantioselectivity. 
 
Figure 3.1 Tandem aminoxylation and O-N bond heterolysis of cyclohexanones. 
 
Figure 3.2 Asymmetric aldol reaction of cyclohexanones with aldehydes. 
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Desymmetrization of cyclohexanone compounds via aldol reaction is one of the first reactions 
that was highly explored.  Gong et al. reported the enantioselective desymmetrization of 4-
substituted cyclohexanones via organocatalytic direct aldol reaction with aldehydes.6  The reaction 
was catalyzed by 4-hydroxy-prolinamide derivative, 7 to generate products, 6 with three chiral 
centers in high enantio- and diastereoselectivities.  Consequently, Rios and Moyano et al. disclosed 
that proline, 8 also could catalyze this reaction with thiourea, 9 as co-catalyst.  The role of thiourea 
was assumed to form hydrogen bonding with the proline carboxylic acid, thereby enhancing the 
Brønsted acidity to activate the aldehyde carbonyl group through hydrogen bonding.7  Bolm et al. 
reported the same reaction catalyzed by L-proline under solvent free conditions using Ball Mill to 
yield high enantioselective products.8 (Figure 3.2) 
 
Figure 3.3 Asymmetric intramolecular aldolization. 
Iwabuchi et al. reported an efficient enantioselective synthesis of bicyclic ketones, by the 
asymmetric intramolecular aldolization of σ-symmetric substrates.  Intramolecular aldolization of 
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10 catalyzed by L-proline gave endo bicyclo compounds, 11 and 12 with excellent 
diastereoselectivity and good enantioselectivity.9 (Figure 3.3) 
Bonjoch developed an interesting microwave-assisted intramolecular aldol reaction for the 
enantioselective synthesis of 2-azabicyclo[3.3.1]nonanes with good yield and moderate 
enantioselectivity.10  The products are formed via proline catalyzed desymmetrization of prochiral 
4-N-protected aminocyclohexanone, 13 through intramolecular aldol cyclization generated 
bicyclic products. (Figure 3.4) 
 
Figure 3.4 Desymmetrization and intramolecular aldolization. 
Siedel in 2010, reported the first catalytic enantioselective Friedländer condensation reaction.  
The synthesis of highly enantioselective quinoline substrates was achieved by the 
desymmetrization of 4-substituted cyclohexanone with O-aminobenzaldehydes.  The products, 17 
formed serve as precursors to tacrine analogues which show activity towards the treatment of 
cognitive disorders such as Alzheimer’s disease.11 (Figure 3.5) 
Cheng and co-workers disclosed functionalized chiral ionic liquids catalyzed asymmetric α-
alkylation of 4-substituted cyclohexanones with secondary alcohols, which can form stable 
carbocations.12  The bromide ion in FCIL was found to be effective to give high enantioselective 
59 
 
products compared to BF4- and PF6- counterparts.  The alcohols that form more stable carbocations 
gave better yields and good enantioselective products. (Figure 3.6) 
Figure 3.5 Enantioselective Friedländer condensation. 
Figure 3.6 Asymmetric alkylation of cyclohexanones catalyzed by functionalized chiral ionic 
liquids (FCIL). 
Xiao et al. reported highly stereoselective desymmetrization of meso-cyclic ketones by 
Michael addition to nitrostyrenes catalyzed by novel bifunctional catalyst.13  The catalyst with 
pyrrolidine backbone and O-phenyl amide linkage provide dual hydrogen bonding with nitro 
group, thus affording Michael adducts with very high enantio- and diastereoselectivities.  Recently, 
Chen et al. has developed Michael addition of ketones to vinyl sulfones.  The desired products are 
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obtained with high enantioselectivities by using either camphor-derived pyrrolidine, 25 or 
cinchonidine-derived amine, 26 as catalyst.14 (Figure 3.7) 
Figure 3.7 Desymmetrization of cyclohexanones by asymmetric Michael addition.  
Maruoka et al.  discovered an excellent bis-aluminium Lewis acid catalyzed ring expansion 
reaction of substituted cyclohexanones with α-substituted α-diazo acetates to yield quaternary 
carbon centered seven membered carbocyclic products in high yield and excellent 
enantioselectivities.15  The catalyst was prepared by mixing 3, 3’-bis(trimethylsilyl)-BINOL, (S)-
30 and Me3Al in 1:2 ratio for 1 h.  A wide range of substrates of cyclohexanones with different 
substituents were prepared with high diastereo- and enantioselectivities. (Figure 3.8)  
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Figure 3.8 Catalytic desymmetrizing asymmetric ring expansion.  
Baeyer-Villiger oxidation is one of the very old and valuable reaction for the synthesis of 
lactones from cyclohexanones.  Feng et al. disclosed an efficient synthesis of highly 
enantioselective γ- and ε-lactones from the desymmetrization of cyclobutanones and 
cyclohexanones.16  The reaction was catalyzed by chiral N, N’-dioxide-Sc(III) complex to furnish 
lactones 32 and 33 with excellent enantioselectivities. (Figure 3.9)   
 
Figure 3.9 Asymmetric Baeyer-Villiger Oxidation 
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3.3 Desymmetrization reactions of cyclic ketones catalyzed by chiral BINOL phosphoric 
acid: 
 
Figure 3.10 Chiral BINOL phosphoric acid catalyzed Baeyer-Villiger Oxidation. 
Ding and coworkers, disclosed the first chiral Brønsted acid catalyzed desymmetrization of 3-
substituted cyclobutanones by asymmetric Baeyer-Villiger oxidation with aqueous H2O2.  The 
mechanistic investigations suggest that the reaction proceeds in a two-step concerted mechanism.  
The catalyst coordinates both carbonyl oxygen and peroxide in a bifunctional activation mode, 
there by enhances the dissociation of –OH group from the Criegee intermediate.  The products 
were formed with excellent yield and good enantioselectivities.17 (Figure 3.10)  
List et al. in 2011, developed an elegant asymmetric Fischer indolization reaction catalyzed by 
chiral SPINOL derived phosphoric acid.18  The desymmetrization of protected hydrazones, 35 
which are prepared from condensation with 4-substituted cyclohexanones, occurs via [3,3]-
sigmatropic rearrangement in presence of catalytic amount of phosphoric acid and Amberlite 
CG50 resin to give highly enantioselective products.  The resin functions as a quenching agent for 
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the ammonia byproduct that was produced in the reaction, without hindering the catalytic activity.  
The chiral indole product was further functionalized to the formal synthesis of (S)-Ramatroban. 
Figure 3.11 Catalytic enantioselective Fischer indolization. 
3.4 Desymmetrization of cyclic ketones to form axially chiral compounds: 
Axially chiral compounds, also referred as Atropisomers, exhibit unique chirality due to the 
non-coplanar arrangement of groups about an imaginary axis.  Usually, the axial chirality in a 
molecule arises due to the restricted rotation of a single bond or double bond.19  Following are the 
different types of axially chiral compounds that are found to exist so far. 
 
Figure 3.12 Axially chiral compounds. 
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Axially chiral compounds attracted much attention over the last two decades owing to their 
importance in asymmetric catalysis as chiral ligands and also occurrence in natural products.20  
Tremendous research advances has been made in the synthesis of axially chiral biaryl, allenes and 
sprianes.21  The axially chiral cyclohexylidenes and cyclohexylidene oximes are generally 
synthesized by employing the desymmetrization of cyclohexanones strategy in various asymmetric 
reactions.   
3.4.1 Synthesis of axially chiral cyclohexylidenes: 
Figure 3.13 Asymmetric HWE reaction. 
Denmark et al. in 1992, first reported the synthesis of chiral cyclohexylidenes by asymmetric 
Horner-Wadsworth-Emmons (HWE) reaction employing scalemic phosphonamidates, (cis)-38 as 
chiral auxiliaries.22  Reaction of Lithium salt of the phoshpnamidate anion, 38, with 4-substituted 
cyclohexanones afford 39 as single adduct.  The phosphorous moiety was activated under mild 
basic conditions for the formation of oxaphosphenate, which results in the formation of chiral 
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cyclohexylidenes, 40 with high yield and moderate enantioselectivity.  Tomioka et al. developed 
asymmetric HWE reaction of phosphonates, 41 with substituted cyclohexanones catalyzed by 
external chiral ligand, 42.  In presence of chiral ligand 42, gave (S)-cis-alcohol, 43a and (R)-
trans-alcohol, 43b in a separable diastereomeric mixture in 89% and 5% yields respectively.  
Upon heating 43a in presence of propionic acid and sodium acetate gave (S)-cyclohexylidene 
product, 44 in high yield and good enantioselectivity.23 (Figure 3.13) 
 
Figure 3.14 Asymmetric Peterson reaction.  
Tomioka also reported asymmetric Peterson reaction employing the chiral external ligand strategy, 
using 46 as chiral ligand the reaction of α-trimethylsilanylacetate with substituted cyclohexanones 
furnished desymmetric cyclohexylidene products, 47 in excellent yields and good 
enantioselectivities.24 (Figure 3.14) 
3.4.2 Synthesis of axially chiral cyclohexylidene oximes: 
Since the discovery of cyclohexylidene oximes show optical activity in 1910,25 Toda and Akai 
were first to successfully isolate these chiral compounds by the diastereomeric resolution with 
49.26  By keeping the solution of racemic 48 and chiral 49 at room temperature, a diastereomeric 
compound containing 1:1 ratio of 48:49 was formed as colorless needles.  By treating this with 
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allyl amine, optically pure cyclohexylidene oxime, 50 was formed with 79% ee.  Benzoylation of 
chiral oxime was performed using benzoyl chloride in presence of pyridine.  Since the oxime, 50 
was not stable on HPLC column, the enantioselectivity of 50a was determined using chiral HPLC 
and assigned to 50 analogously.  To show the application of these compounds, in presence of 85% 
H2SO4 the diastereomeric compound (48:49) undergoes Beckmann rearrangement to form lactam, 
51 with 58% yield and 80% enantiomeric excess. (Figure 3.15) 
 
Figure 3.15. First isolation of optically active cyclohexylidene oximes. 
Hoshino et al. in 2004, disclosed kinetic resolution of cyclohexylidene oxime esters by 
transesterification catalyzed by lipase.27  They observed that the use of 5-phenyl valeryl group as 
ester is key in getting high enantioselectivity.  By using using oxime acetates afforded products 
with low enantioselectivities.  The transesterification of 52 proceeded smoothly in presence of 
lipase and the oxime ester 54 was obtained with 93% enantiomeric excess.  These are the only two 
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methods reported for the synthesis of chiral cyclohexylidene oximes and the development of novel 
methodology is highly desired. 
 
Figure 3.16 Enzyme catalyzed kinetic resolution of cyclohexylidene oxime esters. 
3.5 Optimization of reaction conditions for the asymmetric synthesis of cyclohexylidene 
oximes: 
Our investigation started with the reaction of phenoxyamine, 58 with 4-phenyl cyclohexanone, 
59 in presence of chiral BINOL phosphoric acid and phosphate complexes.  We did not observe 
the desired benzofuran product, 61 but instead full conversion of starting materials to the 
condensed product oxime, 60 was observed, surprisingly with 54% enantioselectivity (Table 3.1, 
entry 3).  Screening of different catalysts showed Mg(P1)2 at room temperature afforded 
cyclohexylidene oximes with slight increase in enantioselectivity with 62% ee (Table 3.1, entry 
6). 
68 
 
Table 3.1 Optimization of reaction conditions. 
 Our efforts to further improve the enantioselectivity by optimizing the solvent and 
temperature with Mg(P1)2 as catalyst were not successful (Table 3.2, entries 1 – 7).  To our delight, 
we observed strontium phosphate complex of P1, Sr(P1)2 at -78 °C proved to be the ideal 
conditions to afford 60 with 91% ee (Table 3.2, entry 8).  Surprisingly, this reaction can also be 
catalyzed by P1 with slight less enantioselective products (Table 3.2, entry 9). 
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Table 3.2 Solvent and temperature screening. 
 
3.6 Substrate scope for the asymmetric synthesis of cyclohexylidene oxime ethers: 
A wide range of chiral cyclohexylidene oxime ether substrates were synthesized using this 
methodology.  All substrates are well-tolerated with substituents on the phenyl ring of 
phenoxyamine.  Disubstituted phenyl substrates showed slight increase in enantioselectivity due 
to the steric factors (60d, 60e).  The absolute configuration for 60b was observed to be ‘R’ based 
on the X-ray crystal structure and all other compounds were assigned analogously.   
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Figure 3.17. Substrate scope with different aryloxyamines. 
We then used 3,5-dimethylphenyloxy amine to react with different substrates of 4-substituted 
cyclohexanones.  Electron-releasing groups on para position of the phenyl ring of cyclohexanone 
afforded products with high enantioselectivities (60f, 60g, 60h) compared to electron-withdrawing 
groups (60k, 60l).  Even the alkyl groups at 4-position of cyclohexanone afforded products with 
good enantioselectivities and excellent yields (60m, 60n). 
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Figure 3.18. Substrate scope with different 4-substituted cyclohexanones. 
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3.7 Conclusion: 
To conclude, we have developed the first catalytic asymmetric synthesis of novel axially chiral 
cyclohexylidene oxime ethers by the desymmetrization of 4-substituted cyclohexanones, catalyzed 
by chiral BINOL strontium phosphate to furnish products with excellent yields and good 
enantioselectivities. 
3.8 Experimental data: 
General Considerations: 
All reactions were carried out in flame-dried screw-cap test tubes with magnetic stirring.  All 
anhydrous solvents were purchased from commercial sources and used under Argon atmosphere.  
Chiral (R)-BINOL was purchased from commercial sources and used without further purification.  
H(P1)28 was synthesized according to the literature procedure.  Ca(P1)2,
29 Mg(P1)2, Sr(P1)2
30 were 
prepared as the reported procedures.  Thin layer chromatography was performed on Merck TLC 
plates (silica gel 60 F254).  Flash column chromatography was performed with Merck silica gel 
(230-400 mesh).  Enantiomeric excess (ee) was determined using Agilent 1260 infinity HPLC 
equipped with quaternary pump and Diode-Array detector.  Optical rotations were performed on 
a Rudolph Research Analytical Autopol IV polarimeter (λ 589) using a 700-μL cell with a path 
length of 1-dm.  1HNMR and 13C NMR were recorded on Varian Inova-400 spectrometer and 
Varian-500 spectrometer with chemical shifts reported relative to tetramethylsilane (TMS) in 
CDCl3 solvent.  The HRMS data were measured on an Agilent 1100 LC/MS ESI/TOF mass 
spectrometer with electro-spray ionization.  Compounds described in the literature were 
characterized by comparing their spectral data to the reported values.   
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Experimental Section: 
Synthesis of 4-aryl cyclohexanones: 
All 4-aryl cyclohexanones 59f-59l were synthesized using the following scheme reported by 
List31 and confirmed by comparison of the spectral data.  
Figure 3.19 Synthesis of 4-aryl cyclohexanones. 
59a, 59m, 59n were purchased from commercial sources and used without purification. 
Synthesis of aryloxyamines: 
Aryloxyamines 58a-58d32 and 58e33 were prepared following the literature procedure and 
confirmed by comparison of spectral data. 
Figure 3.20 Synthesis of aryloxyamines. 
74 
 
General procedure for the preparation of chiral 4-substituted cyclohexylidene oxime 
ethers, 60: 
To a flame-dried reaction tube charged with 4Å molecular sieves 50 mg (pre-activated in oven) 
was added 4-phenyl cyclohexanone 59 (0.22 mmol), catalyst Sr[P1]2 (5 mol%), the tube was 
evacuated and filled with argon.  Added anhydrous dichloromethane (1.0 mL) and cooled the 
reaction mixture to -78 °C.  Added O-phenylhydroxylamine 58 (0.15 mmol) to the reaction mixture 
at -78 °C and stirred the reaction at the same temperature for 2 h.  After completion of reaction 
(monitored by TLC) the reaction mixture was directly added on silica gel column and purified by 
flash chromatography (1:10, ether : hexane) to get the pure product 60.  
All racemic substrates were synthesized following the general procedure using diphenyl 
phosphate (5 mol%) as catalyst at room temperature. 
   (R,Z)-4-phenylcyclohexan-1-one O-phenyloxime 
The product was obtained by flash column chromatography (diethyl ether: hexane, 1:10) as 
viscous oil.  Yield: 98%, ee: 91%.  HPLC Analysis: Chiralcel OD-H (Hexane:Isopropanol 98:2, 
1.0 mL/min), t r-major 9.2 min, t r-minor 7.82 min.   [α]20D= -9.6  (c = 2.7, CHCl3).  1H NMR (500 
MHz; CDCl3): δ  7.25-7.21 (m, 4H), 7.15-7.11 (m, 5H), 6.91 (m, 1H), 3.57-3.52 (m, 1H), 2.74 (tt, 
J = 12.2, 3.3 Hz, 1H), 2.64 (m, J = 2.2 Hz, 1H), 2.28 (td, J = 13.8, 4.9 Hz, 1H), 2.10-1.94 (m, 3H), 
1.74-1.59 (m, 2H).  13C NMR (126 MHz; CDCl3): δ 163.0, 159.8, 145.9, 129.6, 128.9, 127.1, 
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126.8, 122.1, 115.0, 44.0, 34.5, 33.4, 32.4, 26.1.  HRMS (ESI) calcd for C18H19NO ([M+H]
+) m/z 
266.1467, found 266.1542. 
  (R,Z)-4-phenylcyclohexan-1-one O-(4-bromophenyl) oxime 
The product was obtained by flash column chromatography (diethyl ether: hexane, 1:10) as 
viscous oil.  Yield: 96%, ee: 91%.  HPLC Analysis: Chiralcel OD-H (Hexane:Isopropanol 98:2, 
1.0 mL/min), t r-major 7.65 min, t r-minor 8.16 min.  [α]20D= -8.4  (c = 0.8, CHCl3).  1H NMR (400 
MHz; CDCl3): δ  7.42-7.38 (m, 2H), 7.34-7.30 (m, 2H), 7.24-7.21 (m, 3H), 7.11-7.07 (m, 2H), 
3.61-3.56 (m, 1H), 2.84 (tt, J = 12.1, 3.3 Hz, 1H), 2.70 (m, J = 2.2 Hz, 1H), 2.36 (td, J = 13.8, 4.9 
Hz, 1H), 2.21-2.02 (m, 3H), 1.83-1.67 (m, 2H).  13C NMR (126 MHz; CDCl3): δ 163.4, 158.9, 
145.7, 132.4, 128.9, 127.0, 126.8, 116.6, 114.1, 43.9, 34.4, 33.3, 32.2, 26.1.  HRMS (ESI) calcd 
for C18H18BrNO ([M+H]
+) m/z 344.0572, found 344.0643. 
 (R,Z)-4-phenylcyclohexan-1-one O-(p-tolyl) oxime             
The product was obtained by flash column chromatography (diethyl ether: hexane, 1:10) as 
viscous oil.  Yield: 99%, ee: 84%.  HPLC Analysis: Chiralcel AD-H (Hexane:Isopropanol 98:2, 
1.0 mL/min), t r-major 4.62 min, t r-minor 5.15 min.  [α]20D= -6.3  (c = 0.11, CHCl3).  1H NMR (400 
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MHz; CDCl3): δ  7.34-7.30 (m, 2H), 7.24-7.21 (m, 3H), 7.13-7.08 (m, 4H), 3.65-3.60 (m, 1H), 
2.83 (tt, J = 12.1, 3.3 Hz, 1H), 2.71 (m, J = 2.2 Hz, 1H), 2.40-2.32 (m, 4H), 2.20-2.02 (m, 3H), 
1.84-1.68 (m, 2H).  13C NMR (126 MHz; CDCl3): δ 162.3, 157.5, 145.7, 131.2, 129.8, 128.7, 
126.9, 126.5, 114.7, 43.8, 34.3, 33.2, 32.1, 25.8, 20.8.  HRMS (ESI) calcd for C19H21NO ([M+H]
+) 
m/z 280.1623, found 280.17. 
 (R,Z)-4-phenylcyclohexan-1-one O-(3,5-dimethylphenyl) oxime 
The product was obtained by flash column chromatography (diethyl ether: hexane, 1:10) as 
viscous oil.  Yield: 98%, ee: 93%.  HPLC Analysis: Chiralcel OD-H (Hexane:Isopropanol 98:2, 
1.0 mL/min), t r-major 7.55 min, t r-minor 7.18 min.  [α]20D= -8.1  (c = 2.2, CHCl3).  1H NMR (500 
MHz; CDCl3): δ  7.25-7.22 (m, 2H), 7.16-7.12 (m, 3H), 6.76 (s, 2H), 6.57 (s, 1H), 3.53 (m, J = 2.1 
Hz, 1H), 2.74 (tt, J = 12.2, 3.3 Hz, 1H), 2.64 (m, J = 2.2 Hz, 1H), 2.28 (td, J = 13.8, 4.9 Hz, 1H), 
2.23 (s, 6H), 2.10-1.93 (m, 3H), 1.66 (m, J = 4.2 Hz, 2H).  13C NMR (126 MHz; CDCl3): δ 162.32, 
159.39, 145.51, 138.98, 128.49, 126.70, 126.36, 123.49, 112.23, 43.62, 34.12, 33.02, 31.96, 25.64, 
21.42.  HRMS (ESI) calcd for C20H23NO ([M+H]
+) m/z 294.178, found 294.1856. 
 (R,Z)-4-phenylcyclohexan-1-one O-(2,4-dinitrophenyl) oxime 
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The product was obtained by flash column chromatography (diethyl ether: hexane, 1:10) as 
yellow solid.  Yield: 94%, ee: 94%.  HPLC Analysis: Chiralcel AD-H (Hexane:Isopropanol 98:2, 
1.0 mL/min), t r-major 17.53 min, t r-minor 16.65 min.  [α]20D= -33.02  (c = 2.2, CHCl3).  1H NMR (500 
MHz; CDCl3): δ  8.89 (d, J = 2.7 Hz, 1H), 8.43 (dd, J = 9.4, 2.8 Hz, 1H), 8.01 (d, J = 9.4 Hz, 1H), 
7.33 (t, J = 7.6 Hz, 2H), 7.25-7.22 (m, 3H), 3.70-3.66 (m, 1H), 2.88 (tt, J = 12.2, 3.2 Hz, 1H), 2.77 
(m, J = 2.2 Hz, 1H), 2.44 (td, J = 13.8, 5.0 Hz, 1H), 2.26-2.17 (m, 3H), 1.85-1.73 (m, 2H).  13C 
NMR (126 MHz; CDCl3): δ 168.3, 157.8, 144.8, 140.6, 136.0, 129.5, 128.8, 126.80, 126.78, 122.2, 
117.3, 43.4, 34.1, 33.0, 31.7, 27.1.  HRMS (ESI) calcd for C18H17N3O5 ([M+Na]
+) m/z 378.1168, 
found 378.1221. 
 (R,Z)-4-(p-tolyl)cyclohexan-1-one O-(3,5-dimethylphenyl) oxime 
The product was obtained by flash column chromatography (diethyl ether: hexane, 1:10) as 
liquid.  Yield: 98%, ee: 90%.  HPLC Analysis: Chiralcel AD-H (Hexane:Isopropanol 98:2, 1.0 
mL/min), t r-major 4.32 min, t r-minor 4.98 min.  [α]20D= -2.5  (c = 1.55, CHCl3).  1H NMR (500 MHz; 
CDCl3): δ  7.16-7.12 (m, 4H), 6.85 (s, 2H), 6.67 (s, 1H), 3.64-3.60 (m, 1H), 2.81 (tt, J = 12.1, 3.3 
Hz, 1H), 2.73 (m, J = 2.2 Hz, 1H), 2.38 (m, 1H), 2.35 (s, 3H), 2.33 (s, 6H), 2.18-2.02 (m, 3H), 
1.82-1.67 (m, 2H).  13C NMR (126 MHz; CDCl3): δ 162.7, 159.7, 142.8, 139.3, 136.2, 129.5, 
126.9, 123.8, 112.5, 43.5, 34.5, 33.4, 32.3, 26.0, 21.7, 21.3.  HRMS (ESI) calcd for C21H25NO 
([M+H]+) m/z 308.1936, found 308.2025. 
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(R,Z)-4-(4-methoxyphenyl)cyclohexan-1-one O-(3,5-dimethylphenyl) oxime 
The product was obtained by flash column chromatography (diethyl ether: hexane, 1:10) as 
liquid.  Yield: 99%, ee: 86%.  HPLC Analysis: Chiralcel AD-H (Hexane:Isopropanol 98:2, 1.0 
mL/min), t r-major 6.34 min, t r-minor 7.75 min.  [α]20D= -3.06  (c = 4, CHCl3).  1H NMR (400 MHz; 
CDCl3): δ  7.19-7.16 (m, 2H), 6.91-6.88 (m, 4H), 6.68 (s, 1H), 3.82 (s, 3H), 3.63 (m, 1H), 2.84-
2.73 (m, 2H), 2.41-2.37 (m, 1H), 2.35 (s, 6H), 2.18-2.03 (m, 3H), 1.78-1.67 (m, 2H).  13C NMR 
(101 MHz; CDCl3): δ 162.7, 159.7, 158.4, 139.3, 138.0, 127.9, 123.8, 114.2, 112.6, 55.5, 43.1, 
34.7, 33.6, 32.3, 26.0, 21.7.  HRMS (ESI) calcd for C21H25NO2 ([M+H]
+) m/z 324.1885, found 
324.1972. 
  
(R,Z)-4-(4-(tert-butyl)phenyl)cyclohexan-1-one O-(3,5-dimethylphenyl) oxime 
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The product was obtained by flash column chromatography (diethyl ether: hexane, 1:10) as 
liquid.  Yield: 99%, ee: 86%.  HPLC Analysis: Chiralcel AD-H (Hexane:Isopropanol 98:2, 1.0 
mL/min), t r-major 3.61 min, t r-minor 4.48 min.  [α]20D= -4.23  (c = 4.3, CHCl3).  1H NMR (400 MHz; 
CDCl3): δ  7.38 (d, J = 7.9 Hz, 2H), 7.19 (d, J = 7.6 Hz, 2H), 6.88 (s, 2H), 6.69 (s, 1H), 3.64 (m, 
1H), 2.87-2.73 (m, 2H), 2.42-2.38 (m, 7H), 2.21-2.03 (m, 3H), 1.81-1.71 (m, 2H), 1.36 (s, 9H).  
13C NMR (101 MHz; CDCl3): δ 162.7, 159.7, 149.4, 142.7, 139.2, 126.6, 125.6, 123.7, 112.5, 43.3, 
34.63, 34.44, 33.3, 32.3, 31.6, 25.9, 21.7.  HRMS (ESI) calcd for C24H31NO ([M+H]
+) m/z 
350.2406, found 350.2490.  
 
(R,Z)-4-(naphthalen-1-yl)cyclohexan-1-one O-(3,5-dimethylphenyl) oxime 
The product was obtained by flash column chromatography (diethyl ether: hexane, 1:10) as 
liquid.  Yield: 97%, ee: 85%.  HPLC Analysis: Chiralcel OD-H (Hexane:Isopropanol 98:2, 1.0 
mL/min), t r-major 14.13 min, t r-minor 15.36 min.  [α]20D= +23.98  (c = 3, CHCl3).    1H NMR (400 
MHz; CDCl3): δ  8.18 (d, J = 8.4 Hz, 1H), 7.92 (d, J = 7.9 Hz, 1H), 7.77 (d, J = 8.1 Hz, 1H), 7.62-
7.38 (m, 4H), 6.91 (s, 2H), 6.70 (s, 1H), 3.70 (m, 2H), 2.85 (m, 1H), 2.54 (td, J = 13.6, 4.2 Hz, 
1H), 2.36-2.17 (m, 9H), 1.98-1.80 (m, 2H).  13C NMR (101 MHz; CDCl3): δ 162.6, 159.8, 141.6, 
139.3, 134.3, 131.5, 129.4, 127.2, 126.3, 125.94, 125.76, 123.9, 123.1, 122.6, 112.6, 38.7, 34.0, 
32.9, 32.6, 26.3, 21.8.  HRMS (ESI) calcd for C24H25NO ([M+H]
+) m/z 344.1936, found 344.2014. 
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(R,Z)-4-(3,5-dimethylphenyl)cyclohexan-1-one O-(3,5-dimethylphenyl) oxime 
The product was obtained by flash column chromatography (diethyl ether: hexane, 1:10) as 
gummy liquid.  Yield: 98%, ee: 89%.  HPLC Analysis: Chiralcel AD-H (Hexane:Isopropanol 98:2, 
1.0 mL/min), t r-major 3.84 min, t r-minor 4.43 min.  [α]20D= -3.4  (c = 3.6, CHCl3).  1H NMR (500 
MHz; CDCl3): δ  6.87 (m, 5H), 6.67 (s, 1H), 3.62 (m, J = 2.0 Hz, 1H), 2.81-2.71 (m, 2H), 2.40-
2.33 (m, 13H), 2.18-2.01 (m, 3H), 1.83-1.68 (m, 2H).  13C NMR (126 MHz; CDCl3): δ 162.6, 
159.6, 145.7, 139.1, 138.1, 128.2, 124.7, 123.6, 112.4, 43.7, 34.3, 33.2, 32.2, 25.9, 21.6.  HRMS 
(ESI) calcd for C22H27NO ([M+H]
+) m/z 322.2093, found 322.2173. 
 
(R,Z)-4-(4-(trifluoromethyl)phenyl)cyclohexan-1-one O-(3,5-dimethylphenyl) oxime  
 The product was obtained by flash column chromatography (diethyl ether: hexane, 1:10) as 
yellow solid.  Yield: 98%, ee: 83%.  HPLC Analysis: Chiralcel AD-H (Hexane:Isopropanol 98:2, 
81 
 
1.0 mL/min), t r-major 5.39 min, t r-minor 6.38 min.  [α]20D= -3.5 (c = 3.5, CHCl3).  1H NMR (500 
MHz; CDCl3): δ  7.59 (d, J = 8.3 Hz, 2H), 7.35 (d, J = 8.2 Hz, 2H), 6.88 (s, 2H), 6.69 (s, 1H), 
3.68-3.65 (m, 1H), 2.90 (tt, J = 12.1, 3.0 Hz, 1H), 2.77 (m, J = 2.1 Hz, 1H), 2.43-2.30 (m, 7H), 
2.20-2.04 (m, 3H), 1.84-1.68 (m, 2H).  13C NMR (126 MHz; CDCl3): δ 162.1, 159.8, 149.9, 129.2, 
129.0, 127.5, 125.86, 125.83, 124.0, 123.5, 112.6, 43.9, 34.2, 33.1, 32.2, 25.8, 21.8.  HRMS (ESI) 
calcd for C21H22F3NO ([M+H]
+) m/z 362.1653, found 362.1742. 
 
(R,Z)-4-(4-chlorophenyl)cyclohexan-1-one O-(3,5-dimethylphenyl) oxime 
The product was obtained by flash column chromatography (diethyl ether: hexane, 1:10) as 
gummy liquid.  Yield: 98%, ee: 76%.  HPLC Analysis: Chiralcel AD-H (Hexane:Isopropanol 99:1, 
1.0 mL/min), t r-major 5.6 min, t r-minor 6.98 min.  [α]20D= -4.08  (c = 5.8, CHCl3).  1H NMR (500 
MHz; CDCl3): δ  7.30-7.28 (m, 2H), 7.17-7.15 (m, 2H), 6.85 (s, 2H), 6.67 (s, 1H), 3.64-3.60 (m, 
1H), 2.81 (m, J = 3.8 Hz, 1H), 2.73 (m, J = 2.2 Hz, 1H), 2.37 (m, 7H), 2.16-2.01 (m, 3H), 1.78-
1.64 (m, 2H).  13C NMR (126 MHz; CDCl3): δ 162.1, 159.5, 144.1, 139.1, 132.1, 128.7, 128.2, 
123.7, 112.4, 43.2, 34.2, 33.1, 32.0, 25.7, 21.6.  HRMS (ESI) calcd for C20H22ClNO ([M+H]
+) m/z 
328.139, found 328.1464.  
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 (R,Z)-4-methylcyclohexan-1-one O-phenyl oxime 
The product was obtained by flash column chromatography (diethyl ether: hexane, 1:10) as 
liquid.  Yield: 98%, ee: 80%.  HPLC Analysis: Chiralcel OD-H (Hexane:Isopropanol 99:1, 1.0 
mL/min), t r-major 5.12 min, t r-minor 4.44 min.  [α]20D= -2.5  (c = 0.6, CHCl3).  1H NMR (500 MHz; 
CDCl3): δ  7.31-7.26 (m, 2H), 7.18-7.15 (m, 2H), 6.97 (tt, J = 7.3, 1.1 Hz, 1H), 3.43-3.38 (m, 1H), 
2.55 (m, J = 1.6 Hz, 1H), 2.20 (td, J = 13.5, 4.9 Hz, 1H), 1.99-1.85 (m, 3H), 1.73-1.66 (m, 1H), 
1.28-1.14 (m, 2H), 0.97 (d, J = 6.6 Hz, 3H).  13C NMR (126 MHz; CDCl3): δ 163.6, 159.5, 129.2, 
121.6, 114.5, 35.0, 33.8, 31.9, 31.5, 25.2, 21.5.  HRMS (ESI) calcd for C13H17NO ([M+H]
+) m/z 
204.131, found 204.139. 
 
  (R,Z)-4-ethylcyclohexan-1-one O-phenyl oxime 
The product was obtained by flash column chromatography (diethyl ether: hexane, 1:10) as 
liquid.  Yield: 98%, ee: 92%.  HPLC Analysis: Chiralcel OD-H (Hexane:Isopropanol 99:1, 1.0 
mL/min), t r-major 4.91 min, t r-minor 4.31 min.  [α]20D= -2.9  (c = 0.4, CHCl3).  1H NMR (500 MHz; 
CDCl3): δ  7.30-7.26 (m, 2H), 7.17-7.13 (m, 2H), 6.98-6.95 (m, 1H), 3.43-3.38 (m, 1H), 2.56 (m, 
J = 1.7 Hz, 1H), 2.19 (m, J = 4.9 Hz, 1H), 2.02-1.91 (m, 3H), 1.44 (m, J = 3.7 Hz, 1H), 1.30 (m, 
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2H), 1.25-1.14 (m, 2H), 0.91 (q, J = 9.0 Hz, 3H).  13C NMR (126 MHz; CDCl3): δ 164.1, 159.7, 
129.3, 121.7, 114.7, 38.7, 32.7, 31.65, 31.57, 28.9, 25.4, 11.8.  HRMS (ESI) calcd for C14H19NO 
([M+H]+) m/z 218.1467, found 218.1549. 
3.9 X-ray Crystallography data:  
The X-ray diffraction data for compound 60b were measured on Bruker D8 Venture PHOTON 
100 CMOS system equipped with a Cu Kα INCOATEC ImuS micro-focus source (λ = 1.54178 
Å). Indexing was performed using APEX234 (Difference Vectors method). Data integration and 
reduction were performed using SaintPlus 6.01.35  Absorption correction was performed by multi-
scan method implemented in SADABS.36  Space group was determined using XPREP 
implemented in APEX334. Structure was solved using SHELXS-97 (direct methods) and refined 
using SHELXL-201537 (full-matrix least-squares on F2) through OLEX2 interface program.38  All 
non-hydrogen atoms were refined anisotropically. Hydrogen atoms of –CH, –CH2, groups were 
placed in geometrically calculated positions and were included in the refinement process using 
riding model with isotropic thermal parameters: Uiso(H) = 1.2Ueq(-CH,-CH2). Crystal data and 
refinement conditions are shown in Table 1. Asymmetric unit contains two crystallographically 
independent molecules. Some of observed residual density peaks close to Br atoms could 
potentially come from sample contamination by second isomer sharing the same site in the crystal 
lattice, however low occupancy (<5%) precludes the possibility of further modeling of disorder. 
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ORTEP diagram of 60b deposited in CCDC with number CCDC 1491317. 
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Table 1 Crystal data and structure refinement for 60b. 
Identification code 60b 
Empirical formula C18H18BrNO 
Formula weight 344.24 
Temperature/K 99.97 
Crystal system monoclinic 
Space group P21 
a/Å 8.6817(3) 
b/Å 6.3668(2) 
c/Å 28.2219(9) 
α/° 90 
β/° 97.2250(17) 
γ/° 90 
Volume/Å3 1547.57(9) 
Z 4 
ρcalcg/cm3 1.477 
μ/mm-1 3.595 
F(000) 704.0 
Crystal size/mm3 0.09 × 0.06 × 0.01 
Radiation CuKα (λ = 1.54178) 
2Θ range for data collection/° 6.314 to 138.99 
Index ranges -9 ≤ h ≤ 10, -7 ≤ k ≤ 7, -34 ≤ l ≤ 34 
Reflections collected 15510 
Independent reflections 5403 [Rint = 0.0834, Rsigma = 0.0867] 
Data/restraints/parameters 5403/1/379 
Goodness-of-fit on F2 1.038 
Final R indexes [I>=2σ (I)] R1 = 0.0590, wR2 = 0.1366 
Final R indexes [all data] R1 = 0.0738, wR2 = 0.1449 
Largest diff. peak/hole / e Å-3 1.48/-0.57 
Flack parameter 0.027(17) 
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4 Dynamic Kinetic Resolution of 2-substituted cyclohexanones 
4.1 Introduction: 
Dynamic Kinetic Resolution (DKR) process is one of the prominent methods to get 
enantiopure compounds from racemic substrates.  The DKR process proceeds in combination with 
the kinetic resolution step, in which the in situ racemization or equilibration of the substrate occurs.  
This follows the Curtin-Hammett kinetic conditions, in which the two enantiomers of the substrate 
are induced to equilibrate or racemize at a rate faster than the rate of slow-reacting enantiomer 
with the chiral reagent.  For an efficient DKR process, the rate of racemization of the substrates 
has to be faster than the rate of the both resolution steps (fast and slow).  Also, the rate of resolution 
for one enantiomer has to be faster than that of the other enantiomer.  (Figure 4.1)  Several DKR 
processes has been developed based on asymmetric enzyme catalysis, transition metal catalysis 
and recently organocatalytic methodologies.1  The DKR process has been applied in numerous 
asymmetric transformations involving α-substituted ketones, α-substituted keto esters and amides, 
α-substituted imine derivates etc., to afford chiral products with 100% theoretical yield and 
excellent enantioselectivity.  
 
Figure 4.1 Dynamic Kinetic Resolution (DKR) process. 
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4.2 DKR by asymmetric transfer hydrogenation of 2-substituted cyclohexanones: 
Lassaletta and co-workers first reported the asymmetric transfer hydrogenation of 2-substituted 
cyclic imines by DKR.2  In presence of Ru(II) catalyst, (R,R)-1 and HCO2H/Et3N azeotropic 
mixture used as hydrogen source, the bicyclic imines (3) were reduced to give cis-4 with high yield 
and enantioselectivities.  They also showed that 2-substituted cyclicimines, 5 undergo transfer 
hydrogenation in presence of Ir(III) catalyst, (S,S)-2 to give cis-6 products with moderate yield 
and enantioselecitivities. 
 
Figure 4.2 DKR of imines by asymmetric transfer hydrogenation.  
In 2010, List et al. published an efficient organocatalytic asymmetric reductive amination of 
2-substituted cyclohexanones, 7 with p-anisdine, 8 and Hantzsch ester, 9 catalyzed by chiral 
BINOL phosphoric acid.3  The reaction proceeds with the in situ formation of imine followed by 
reduction with Hantzsch ester via dynamic kinetic resolution to furnish products, 10 with good 
yields and high diastereo- and enantioselectivities.  The reaction also works with 2-substituted 
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cyclopentanones.  They further applied this methodology in the synthesis of perindopril, a long-
acting ACE inhibitor3b. 
Figure 4.3 Asymmetric reductive amination of α-branched ketones. 
In 2011, Ohkuma et al. reported an asymmetric hydrogenation of aryl heterocycloalkyl ketones 
catalyzed by (S,R)-15 through dynamic kinetic resolution process.4  The diastereoselectivity of the 
reaction was essentially controlled by the catalyst via metal chelation with carbonyl oxygen and 
the X group present in the heterocycle in 13 and 14.  Under these conditions, syn alcohols, 16 and 
17 were produced with high diastereo- and enantioselectivities with excellent yields.  The authors 
also showed the synthesis of (S,S)-reboxetine succinate using this methodology, which is a 
selective norepinephrine uptake inhibitor. (Figure 4.4) 
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Figure 4.4 Asymmetric hydrogenation of aryl heterocycloalkyl ketones. 
Recently, Zhou et al. reported ruthenium (II) catalyzed asymmetric hydrogenation of α-aryl 
cyclohexanones, 20 to furnish syn diols with excellent enantio- and diastereoselectivity and good 
yields.  They applied this methodology in the synthesis of molecules such as (-)-α-lycorane, (-)-
CP55940 and tetrahydrocannabinol derivatives that are biologically active.5  They further showed 
the application of this methodology in the asymmetric hydrogenation of α,α’-disubstituted 
cycloketones, 22 resulting in the formation of chiral diols with three continuous stereocenters, 23 
in single step.6  The compounds with five membered ring only gave moderate enantioselectivity 
upto 75% ee, while six and seven membered rings showed high enantioselectivities.  The authors 
noted that both aryl and ester groups were necessary to afford highly enantioselective products. 
(Figure 4.5) 
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Figure 4.5 Asymmetric hydrogenation of α,α’-disubstituted cycloketones. 
4.3 Optimization of reaction conditions for dynamic kinetic resolution of 2-substituted 
cyclohexanones. 
Based on our observation and results from desymmetrization of 4-substituted cyclohexanones, 
we investigated dynamic kinetic resolution of 2-substituted cyclohexanones using the same 
methodology.  Our initial reactions with phenoxy amine with 2-phenyl cyclohexanone in presence 
of Sr(P1)2 under identical conditions gave negligible enantioselectivity.   
Figure 4.6 DKR of 2-phenyl cyclohexanone with phenoxyamine. 
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From our observation, the use of different O-protecting group effects the enantioselectivity of 
the product significantly.  Upon using O-(2,4-dinitrophenyl)hydroxylamine in dichloromethane at 
-78 °C in presence of Mg(P1)2 gave product with 38% ee (Table 4.1, entry 3).  Changing the 
solvent to toluene provided excellent enantioselectivity with moderate yield.  Screening the 
optimal temperature for the reaction showed, the yield and enantioselectivity are  
Table 4.1 Optimization for DKR of 2-substituted cyclohexanones. 
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inversely proportional.  At low temperatures high enantioselectivity was observed but with low 
yield (Table 4.1, entries 6 – 10).  This was attributed to the probable decomposition of 27 in the 
reaction conditions to 2, 4-dinitrophenol.  Interestingly, chiral BINOL phosphoric acid, P1 also 
could catalyze the dynamic kinetic resolution process with good yield and enatioselectivity.    
Figure 4.7 Substrate scope for the DKR of 2-substituted cyclohexanones. 
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4.4 Substrate scope for the DKR of 2-substituted cyclohexanones: 
With the optimal conditions, a wide range of substrates are screened using this methodology.  
Both electron releasing and with-drawing groups on the phenyl group of cyclohexanones are 
tolerated providing good enantioselectivities with moderate yields.  This method not only works 
with aryl groups, but also for methyl and chloro groups at the 2-position of the cyclohexanone to 
furnish products with excellent yields. 
 
Figure 4.8 Reductive cleavage and acylation. 
To further extend the utility of this reaction, the oxime ether was reduced to amines in presence 
of 3 eq. of BH3.THF in THF at room temperature.
7  The crude amine intermediate obtained was 
subjected to acylation conditions without purification resulting in the formation of cis-29 product 
with 66% yield and 83% ee.  The NMR and HPLC data of the acylated amine obtained, cis-29 are 
in correlation with the literature data8 reported previously and the configuration for the 2-
substituted chiral cyclohexanone oxime ethers were assigned analogously. 
4.5 Conclusion: 
In conclusion, we have developed a novel asymmetric dynamic kinetic resolution process of 
α-branched cyclohexanones to give 2-substituted cyclohexanone oxime ethers in good yield and 
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enantioselectivities.  Furthermore, we showed the utility of these compounds in the synthesis of 
chiral syn-2-phenyl cyclohexylamines which are useful synthetic intermediates with excellent 
diastereoselectivity and good enantioselectivity. 
4.6 Experimental data: 
General considerations: 
All reactions were carried out in flame-dried screw-cap test tubes with magnetic stirring.  All 
anhydrous solvents were purchased from commercial sources and used under Argon atmosphere.  
Chiral (R)-BINOL was purchased from commercial sources and used without further purification.  
H(P1)9 was synthesized according to the literature procedure.  Ca(P1)2,
10 Mg(P1)2, Sr(P1)2
11 were 
prepared as the reported procedures.  Thin layer chromatography was performed on Merck TLC 
plates (silica gel 60 F254).  Flash column chromatography was performed with Merck silica gel 
(230-400 mesh).  Enantiomeric excess (ee) was determined using a Agilent 1260 infinity HPLC 
equipped with quaternary pump and Diode-Array detector.  Optical rotations were performed on 
a Rudolph Research Analytical Autopol IV polarimeter (λ 589) using a 700-μL cell with a path 
length of 1-dm.  1HNMR and 13C NMR were recorded on Varian Inova-400 spectrometer and 
Varian-500 spectrometer with chemical shifts reported relative to tetramethylsilane (TMS) in 
CDCl3 solvent.  The HRMS data were measured on an Agilent 1100 LC/MS ESI/TOF mass 
spectrometer with electro-spray ionization.  Compounds described in the literature were 
characterized by comparing their spectral data to the reported values. 
Synthesis of 2-aryl cyclohexanones: 
Compounds 25b-25f12 were prepared following the literature procedure and confirmed by 
comparison of spectral data. 25a, 25g, 25h were purchased from commercial sources. 
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General procedure for the preparation of 2-substituted cyclohexanone oxime ethers, 6: 
To a flame-dried reaction tube charged with 4Å molecular sieves 20 mg (pre-activated in oven) 
was added 2-phenyl cyclohexanone 25a (0.05 mmol), catalyst P1 (5 mol%), the tube was 
evacuated and filled with argon.  Added dry toluene (1.0 ml) and cooled the reaction mixture to -
78 °C.  Added O-(2,4-dinitrophenyl)hydroxylamine 27 (0.07 mmol) to the reaction mixture at -78 
°C and stirred the reaction mixture at -78 °C to -65 °C for 20 h.  After completion of reaction 
(monitored by TLC) the reaction mixture was directly added on silica gel column and purified by 
flash chromatography (1:10, ether : hexane) to get the pure product 28. 
 
In the synthesis of racemic substrates upon using diphenylphosphate as catalyst E-oxime was 
observed as major isomer, whereas using P1 at rt gave Z-oxime as major isomer.  In order to have 
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clear comparison between racemic and chiral substrates for HPLC, all racemic substrates were 
prepared using P1 (5 mol%) in dichloromethane at rt. 
(R,Z)-2-phenylcyclohexan-1-one O-(2,4-dinitrophenyl) oxime 
The product was obtained by flash column chromatography (diethyl ether: hexane, 1:10) as 
liquid.  Yield: 86%, ee: 88%. HPLC Analysis: Chiralcel OD-H (Hexane:Isopropanol 99:1, 1.0 
mL/min), t r-major 18.81 min, t r-minor 16.47 min.  [α]20D= +276.42  (c = 1.1, CHCl3).  1H NMR (500 
MHz; CDCl3): δ  8.88 (d, J = 2.8 Hz, 1H), 8.44 (dd, J = 9.4, 2.8 Hz, 1H), 8.05 (d, J = 9.4 Hz, 1H), 
7.38-7.26 (m, 4H), 7.24-7.23 (m, 1H), 5.01 (d, J = 4.9 Hz, 1H), 2.59-2.48 (m, 2H), 2.33 (m, 1H), 
2.05 (m, 1H), 1.97-1.90 (m, 1H), 1.75-1.68 (m, 2H), 1.67-1.61 (m, 1H).  13C NMR (126 MHz; 
CDCl3): δ 170.8, 157.9, 140.8, 138.4, 136.2, 129.7, 129.2, 127.5, 127.1, 122.4, 117.7, 39.8, 29.7, 
29.4, 27.1, 21.0.  HRMS (ESI) calcd for C18H17N3O5 ([M+Na]
+) m/z 378.1168, found 378.1050. 
 (R,Z)-2-(p-tolyl)cyclohexan-1-one O-(2,4-dinitrophenyl) oxime 
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The product was obtained by flash column chromatography (diethyl ether: hexane, 1:10) as 
liquid.  Yield: 84%, ee: 84%. HPLC Analysis: Chiralcel OD-H (Hexane:Isopropanol 99:1, 1.0 
mL/min), t r-major 14.55 min, t r-minor 13.28 min.  [α]20D= +222.9  (c = 1.3, CHCl3).  1H NMR (500 
MHz; CDCl3): δ  8.87 (d, J = 2.7 Hz, 1H), 8.43 (dd, J = 9.4, 2.8 Hz, 1H), 8.05 (d, J = 9.4 Hz, 1H), 
7.18-7.13 (m, 4H), 4.97 (d, J = 4.6 Hz, 1H), 2.56 (m, 1H), 2.48 (m, J = 2.8 Hz, 1H), 2.37-2.30 (m, 
4H), 2.04 (m, J = 2.5 Hz, 1H), 1.91 (m, J = 5.7 Hz, 1H), 1.71 (m, 2H), 1.66-1.59 (m, 1H).  13C 
NMR (126 MHz; CDCl3): δ 171.0, 158.0, 140.8, 136.8, 135.3, 129.9, 129.7, 128.2, 127.4, 122.4, 
117.7, 39.5, 29.8, 29.4, 27.2, 21.3, 21.1.  HRMS (ESI) calcd for C19H19N3O5 ([M+Na]
+) m/z 
392.1325, found 392.1212. 
 (R,Z)-2-(m-tolyl)cyclohexan-1-one O-(2,4-dinitrophenyl) oxime 
The product was obtained by flash column chromatography (diethyl ether: hexane, 1:10) as 
liquid.  Yield: 83%, ee: 82%. HPLC Analysis: Chiralcel OD-H (Hexane:Isopropanol 99:1, 0.7 
mL/min), t r-major 18.41 min, t r-minor 17.3 min.  [α]20D= +233.5  (c = 0.5, CHCl3).  1H NMR (500 
MHz; CDCl3): δ  8.87 (d, J = 2.7 Hz, 1H), 8.43 (dd, J = 9.4, 2.7 Hz, 1H), 8.04 (d, J = 9.4 Hz, 1H), 
7.23-7.20 (m, 1H), 7.07-7.04 (m, 3H), 4.96 (d, J = 4.4 Hz, 1H), 2.56 (dd, J = 14.3, 0.7 Hz, 1H), 
2.48 (dt, J = 14.5, 2.2 Hz, 1H), 2.37-2.31 (m, 4H), 2.04 (m, J = 2.6 Hz, 1H), 1.91 (m, J = 5.7 Hz, 
1H), 1.71 (m, 2H), 1.66-1.60 (m, 1H).  13C NMR (126 MHz; CDCl3): δ 170.8, 157.8, 140.7, 138.8, 
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138.3, 129.5, 129.0, 128.2, 127.8, 124.4, 122.3, 117.6, 39.7, 29.8, 29.4, 27.1, 21.8, 21.0.  HRMS 
(ESI) calcd for C19H19N3O5 ([M+Na]
+) m/z 392.1325, found 392.1223. 
 
(R,Z)-2-(3,5-dimethylphenyl)cyclohexan-1-one O-(2,4-dinitrophenyl) oxime 
The product was obtained by flash column chromatography (diethyl ether: hexane, 1:10) as 
liquid.  Yield: 79%, ee: 82%. HPLC Analysis: Chiralcel OD-H (Hexane:Isopropanol 99:1, 0.7 
mL/min), t r-major 14.48 min, t r-minor 14.00 min.  [α]20D= +236.38  (c = 0.6, CHCl3).  1H NMR (500 
MHz; CDCl3): δ  8.87 (d, J = 2.7 Hz, 1H), 8.43 (dd, J = 9.4, 2.8 Hz, 1H), 8.05 (d, J = 9.4 Hz, 1H), 
6.87 (d, J = 7.8 Hz, 3H), 4.92 (d, J = 4.3 Hz, 1H), 2.58-2.55 (m, 1H), 2.49-2.45 (m, 1H), 2.39-2.33 
(m, 1H), 2.29 (s, 6H), 2.04 (m, 1H), 1.89 (m, J = 5.6 Hz, 1H), 1.73-1.68 (m, 2H), 1.63 (t, J = 8.2 
Hz, 1H).  13C NMR (126 MHz; CDCl3): δ 171.0, 157.9, 140.8, 138.7, 138.3, 129.6, 128.7, 125.3, 
122.4, 117.7, 39.8, 29.9, 29.5, 27.2, 21.8, 21.1.  HRMS (ESI) calcd for C20H21N3O5 ([M+Na]
+) 
m/z 406.1481, found 406.1365. 
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(R,Z)-2-(4-bromophenyl)cyclohexan-1-one O-(2,4-dinitrophenyl) oxime 
The product was obtained by flash column chromatography (diethyl ether: hexane, 1:10) as 
gummy liquid.  Yield: 66%, ee: 90%. HPLC Analysis: Chiralcel OD-H (Hexane:Isopropanol 99:1, 
1.0 mL/min), t r-major 20.84 min, t r-minor 19.94 min.  [α]20D= +239.3  (c = 1.4, CHCl3).  1H NMR 
(500 MHz; CDCl3): δ  8.88 (d, J = 2.8 Hz, 1H), 8.44 (dd, J = 9.4, 2.7 Hz, 1H), 8.04 (d, J = 9.4 Hz, 
1H), 7.46 (d, J = 8.6 Hz, 2H), 7.15 (dd, J = 8.6, 0.7 Hz, 2H), 4.94 (d, J = 4.5 Hz, 1H), 2.61-2.57 
(m, 1H), 2.46-2.42 (m, 1H), 2.28 (m, 1H), 2.05 (m, J = 2.3 Hz, 1H), 1.97-1.90 (m, 1H), 1.73-1.61 
(m, 3H).  13C NMR (126 MHz; CDCl3): δ 170.1, 157.7, 141.0, 137.5, 132.3, 130.2, 129.7, 129.3, 
122.4, 121.1, 117.6, 39.4, 29.7, 29.4, 26.9, 21.0.  HRMS (ESI) calcd for C18H16BrN3O5 ([M+Na]
+) 
m/z 458.0273, found 458.0151. 
 (R,Z)-2-(4-chlorophenyl)cyclohexan-1-one O-(2,4-dinitrophenyl) oxime   
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The product was obtained by flash column chromatography (diethyl ether: hexane, 1:10) as 
solid.  Yield: 68%, ee: 90%. HPLC Analysis: Chiralcel OD-H (Hexane:Isopropanol 99:1, 1.0 
mL/min), t r-major 19.72 min, t r-minor 19.10 min.  [α]20D= +232.6  (c = 1.3, CHCl3).  1H NMR (500 
MHz; CDCl3): δ  8.88 (d, J = 2.8 Hz, 1H), 8.44 (dd, J = 9.4, 2.8 Hz, 1H), 8.04 (d, J = 9.4 Hz, 1H), 
7.35-7.29 (m, 2H), 7.23-7.20 (m, 2H), 4.96 (d, J = 4.6 Hz, 1H), 2.59 (m, 1H), 2.49-2.42 (m, 1H), 
2.32-2.25 (m, 1H), 2.16-2.13 (m, 1H), 2.05 (m, J = 2.3 Hz, 1H), 1.97-1.90 (m, 1H), 1.74-1.68 (m, 
2H).  13C NMR (126 MHz; CDCl3): δ 170.2, 157.7, 141.0, 136.9, 136.2, 133.0, 129.7, 129.4, 129.0, 
122.5, 117.7, 39.3, 29.7, 29.4, 27.0, 21.0.  HRMS (ESI) calcd for C18H16ClN3O5 ([M+Na]
+) m/z 
412.0778, found 412.0676.  
 (R,Z)-2-chlorocyclohexan-1-one O-(2,4-dinitrophenyl) oxime 
The product was obtained by flash column chromatography (diethyl ether: hexane, 1:10) as 
solid.  Yield: 56%, ee: 90%. HPLC Analysis: Chiralcel AD-H (Hexane:Isopropanol 99:1, 1.0 
mL/min), t r-major 11.85 min, t r-minor 15.11 min.  [α]20D= +36.4  (c = 0.8, CHCl3).  1H NMR (500 
MHz; CDCl3): δ  8.92 (d, J = 2.7 Hz, 1H), 8.44 (dd, J = 9.4, 2.7 Hz, 1H), 7.97 (d, J = 9.4 Hz, 1H), 
5.74 (s, 1H), 2.78 (td, J = 14.1, 5.1 Hz, 1H), 2.53 (m, 1H), 2.28-2.24 (m, 1H), 2.10-2.04 (m, 1H), 
1.97 (m, J = 2.7 Hz, 2H), 1.74-1.71 (m, 2H).  13C NMR (126 MHz; CDCl3): δ 166.9, 165.6, 157.2, 
141.3, 129.8, 122.5, 117.5, 48.8, 34.2, 27.5, 26.5, 19.6.   
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 (R,Z)-2-methylcyclohexan-1-one O-(2,4-dinitrophenyl) oxime 
The product was obtained by flash column chromatography (diethyl ether: hexane, 1:10) as 
mixture of diastereomers as solid.  Yield: 77%, ee: 94%. HPLC Analysis for major diastereomer: 
Chiralcel OJ-H (Hexane:Isopropanol 99:1, 0.7 mL/min), t r-major 35.78 min, t r-minor 35.00 min.  
[α]20D= +24.35  (c = 2.2, CHCl3).  1H NMR (500 MHz; CDCl3): δ  8.87 (d, J = 2.8 Hz, 1H), 8.41 
(m, J = 9.4, 3.5, 2.8 Hz, 1H), 7.97 (m, J = 9.4, 3.1 Hz, 1H), 3.30-3.25 (m, 1H), 2.55-2.45 (m, 1H), 
2.37 (m, J = 14.0, 5.3 Hz, 1H), 2.25-2.19 (m, 1H), 2.04-1.98 (m, 1H), 1.93-1.80 (m, 1H), 1.73-
1.63 (m, 2H), 1.55-1.41 (m, 1H), 1.25-1.21 (m, 3H).    13C NMR (126 MHz; CDCl3): δ 172.9, 
172.0, 158.12, 157.93, 140.4, 136.0, 129.47, 129.45, 122.2, 117.34, 117.31, 37.8, 35.8, 31.8, 29.6, 
28.0, 26.71, 26.62, 26.44, 24.4, 20.1, 16.85, 16.82.  HRMS (ESI) calcd for C13H15N3O5 ([M+H]
+) 
m/z 294.1012, found 294.1087. 
Synthesis of cis-N-((1R,2R)-2-phenylcyclohexyl)acetamide, 7:7, 8 
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In a flame-dried reaction tube dissolved 28a (0.03 mmol) in 1 mL of dry tetrahydrofuran (THF) 
under Ar atmosphere and cooled to 0 °C.  Added BH3. THF (0.08 mmol) and stirred the reaction 
mixture at rt until full conversion of starting material (monitored by TLC).  Quenched the reaction 
mass with water (1 mL) and extracted with diethyl ether (2 mL).  The pH of aqueous layer was 
adjusted to alkaline using 1M NaOH solution and extracted with diethyl ether (2 mL) three times.  
The combined organic layer was washed with brine (2 mL), treated with Na2SO4, filtered and 
concentrated to give crude reduced product (1R,2R)-2-phenylcyclohexylamine.  The crude (1R, 
2R)-2-phenylcyclohexylamine was dissolved in diethylether (1 mL), added trimethylamine (0.07 
mmol) followed by acetic anhydride (0.07 mmol) and stirred at room temperature for 4 h.  
Quenched with sat. NaHCO3 solution (1 mL) and extracted with diethylether (2 mL) three times.  
The organic layer was treated with Na2SO4, filtered and concentrated.  The crude product was 
purified by preparative TLC to give pure cis-29 as white solid. 
Yield: 66%, ee: 82%. HPLC Analysis: Chiralcel OD-H (Hexane:Isopropanol 92:8, 0.8 
mL/min), t r-major 10.69 min, t r-minor 16.63 min.  [α]20D = -16  (c = 0.2, CHCl3).  1H NMR (500 MHz; 
CDCl3): δ  7.31-7.28 (m, 2H), 7.21 (m, 3H), 5.37 (s, 1H), 4.39 (m, 1H), 2.96 (dt, J = 12.1, 3.7 Hz, 
1H), 2.01 (m, J = 2.6 Hz, 1H), 1.94-1.88 (m, 2H), 1.79 (s, 3H), 1.71-1.62 (m, 3H), 1.45-1.39 (m, 
2H).  13C NMR (126 MHz; CDCl3): δ 169.7, 143.2, 128.7, 127.7, 126.9, 50.0, 45.0, 31.2, 26.3, 
25.8, 23.9, 21.3.  HRMS (ESI) calcd for C14H19NO ([M+H]
+) m/z 218.1467, found 218.1541. 
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Appendix I 
HPLC and NMR data for Chapter 2 
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Appendix II 
NMR and HPLC data for Chapter 3. 
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Appendix III 
NMR and HPLC data for Chapter 4. 
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